US20090012629A1 - Compositions and methods for tissue repair - Google Patents
Compositions and methods for tissue repair Download PDFInfo
- Publication number
- US20090012629A1 US20090012629A1 US12/101,553 US10155308A US2009012629A1 US 20090012629 A1 US20090012629 A1 US 20090012629A1 US 10155308 A US10155308 A US 10155308A US 2009012629 A1 US2009012629 A1 US 2009012629A1
- Authority
- US
- United States
- Prior art keywords
- implant
- tissue
- mold
- defect
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/38—Joints for elbows or knees
- A61F2/3859—Femoral components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
- A61F2002/30764—Cartilage harvest sites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2/30942—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
- A61F2002/30957—Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using a positive or a negative model, e.g. moulds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
- A61F2002/30971—Laminates, i.e. layered products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/46—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor
- A61F2002/4635—Special tools or methods for implanting or extracting artificial joints, accessories, bone grafts or substitutes, or particular adaptations therefor using minimally invasive surgery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Definitions
- tissue defects such as cartilage tissue defects
- Materials have been developed to fill spaces comprising tissue defects, but have typically been two-dimensional, comprising, for example, a flat sheet cut to approximate the dimensions of a tissue defect, or a layer of cells grown in vitro, from which a two dimensional sheet of cells is applied to a tissue defect.
- U.S. Pat. No. 5,067,964 to Richmond et al. discloses an articular cartilage repair piece and methods of forming.
- This patent discloses a repair piece which includes a backing layer of non-woven, felted fibrous material which is conformable to flat and curved surfaces.
- U.S. Pat. Nos. 5,655,546 and 6,179,871 to Halpern disclose methods for repairing a cartilage defect, comprising the provision of apertures in the cartilage by drilling holes at the base of the cartilage defect.
- the holes may enter the mesenchymal depot.
- a porous scaffold material containing a plurality of magnetic particles is introduced into the apertures.
- magnetically-tagged cartilage growth promoting materials such as chondrocytes or growth factors are injected into the area of the defect.
- U.S. Pat. No. 6,443,988 to Felt et al. discloses methods and apparatuses for repairing a tissue site. The method involves use of a curable polyurethane adapted to be mixed at time of use in order to provide a flowable composition and initiate cure.
- U.S. Pat. Nos. 6,511,958 and 6,514,514 to Atkinson et al. disclose devices and products for repair of cartilage lesions, comprising a cartilage repair matrix suitable for conforming to a cartilage defect and a cartilage-inducing composition on or within the matrix.
- these methods comprise forming, on a tissue defect of a subject, a mold conforming to the contours of at least a portion of the tissue defect, removing the mold from the defect, forming in the mold an implant comprising one or more tissue particles and a biocompatible carrier, whereby the implant has a shape substantially conforming to the contours of at least the portion of the tissue defect, separating the implant from the mold, and applying the implant to at least the portion of the tissue defect.
- the mold comprises for example a pliable substrate having shape memory, which in one embodiment is a sterile substrate.
- the substrate having shape memory is for example a metal foil such as aluminum foil, a plastic, or a polymer such as a polyurethane or a curable plastic.
- the substrate may be a material permeable to liquid.
- the one or more tissue particles are in one embodiment initially suspended in a liquid medium which can be a cell, tissue or organ storage medium.
- forming the implant includes removing an amount of the liquid medium from the mold. The liquid medium may be removed by introducing one or more perforations in the mold, thereby promoting draining of the liquid medium from the mold.
- the mold is made of a substrate material initially having perforations therethrough, or of a substrate material that is permeable to liquid.
- the liquid medium may be further removed by contacting the mold with an absorbent pad.
- the method further comprises distributing the tissue particles substantially uniformly in the mold.
- the biocompatible carrier can include at least one biocompatible polymer such as a fibrinogen, a fibrin, a thrombin, a type I collagen, a type II collagen, a type III collagen, a gelatin, a fibronectin, a laminin, a hyaluronic acid, a hydrogel, a pegylated hydrogel or a chitosan.
- the biocompatible carrier may include at least one biocompatible adhesive such as a fibrin adhesive.
- the implant may further comprise at least one bioactive agent such as a growth factor.
- the growth factor can be selected for example from among a TGF- ⁇ , a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF and an activin.
- the at least one bioactive agent may be a bioactive peptide.
- forming in the mold an implant comprises forming an implant including a first layer including the one or more tissue particles and a second layer comprising the biocompatible carrier.
- the second layer may further include at least one bioactive agent, which can be a growth factor which can be selected from among a TGF- ⁇ , a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF and an activin.
- the at least one bioactive agent in a second layer of the implant can be a bioactive peptide.
- applying the implant to the tissue defect includes inserting the implant at the tissue defect. Applying the implant to the tissue defect can further comprise affixing the implant to the tissue defect. Inserting the implant at the tissue defect can include inserting the implant using a minimally invasive surgical technique, such as arthroscopically.
- the biocompatible carrier can be a biocompatible gel, such as a starch gel, an agarose gel, a polyacrylamide gel or a combination thereof.
- the carrier that includes at least one biocompatible polymer may be autologous to the subject.
- the subject of treatment using the method is a non-human mammal, or is a human in need of treatment of the tissue defect.
- the contours of the tissue defect being treated are three-dimensional. In one aspect the contours of the tissue defect can be substantially cylindrical.
- a method of repairing a tissue defect includes forming, on a tissue defect in a subject, a mold having a surface conforming substantially to contours of the tissue defect, wherein the mold comprises a bioabsorbable substrate having shape memory, removing the mold from the tissue defect, forming within the mold an implant comprising at least a first layer, wherein the first layer comprises one or more tissue particles and a biocompatible carrier, whereby the implant has a shape substantially conforming to the contours of the tissue defect; and applying the mold and implant to the tissue defect.
- the bioabsorbable substrate having shape memory is sterile.
- the bioabsorbable substrate having shape memory is for example a plastic, which can be a bioabsorbable polymer such as a bioabsorbable polyester.
- the bioabsorbable polymer can be a polyester selected from among a polylactic acid, a polyglycolic acid, and a co-polymer comprising a polylactic acid and a polyglycolic acid.
- the method may further include distributing the tissue particles substantially uniformly throughout the first layer.
- the second layer includes for example at least one biocompatible carrier.
- the second layer can include at least one bioactive agent such as a growth factor.
- a method for repairing a tissue defect in a subject which includes forming, on the tissue defect a mold having a surface substantially conforming to the contours of at least a portion of the tissue defect, removing the mold from the tissue defect, forming within the mold an implant comprising one or more tissue particles and a biocompatible carrier, whereby the implant has a shape substantially conforming to the contours of the portion of the tissue defect, applying the mold and implant together to the portion tissue defect, and separating the implant from the mold after applying to the tissue defect.
- Applying the implant to the tissue defect may include inserting the implant at the tissue defect and may further include affixing the implant to the tissue defect. Inserting the implant at the tissue defect may include inserting the implant using a minimally invasive surgical technique such as arthroscopically.
- apparatus for forming an implant for repairing a tissue defect, the apparatus including a mold having a shape substantially conforming to the contours of a tissue defect of a subject, and a composition including one or more tissue particles and a biocompatible carrier, the composition disposed in the mold wherein the shape of the composition substantially conforms to the contours of the tissue defect.
- the mold is formed from a substrate having shape memory such as for example a metal foil such as aluminum foil, a plastic, or a polymer such as a polyurethane or a curable plastic.
- the substrate may be for example a sterile substrate.
- the substrate may be a material permeable to liquid.
- the substrate may be a bioabsorbable substrate having shape memory such as a bioabsorbable polymer including a bioabsorbable polyester which may be selected from a polylactic acid, a polyglycolic acid, and a co-polymer comprising a polylactic acid and a polyglycolic acid.
- the mold may have one or more perforations therethrough for draining excess liquid medium.
- the tissue particles can be cartilage tissue particles such as neocartilage particles, juvenile cartilage particles, cadaver cartilage particles, or may be selected from among bone tissue particles, liver tissue particles, renal tissue particles, neuronal tissue particles, muscle tissue particles, adipose tissue particles, and a combination thereof.
- the apparatus includes in some aspects the tissue particles distributed substantially uniformly in the mold.
- the biocompatible carrier may include at least one biocompatible adhesive such as a fibrin adhesive.
- the biocompatible carrier can include at least one biocompatible polymer such as a fibrinogen, a fibrin, a thrombin, a type I collagen, a type II collagen, a type III collagen, a gelatin, a fibronectin, a laminin, a hyaluronic acid, a hydrogel, a pegylated hydrogel or a chitosan.
- a biocompatible polymer may be autologous to the subject.
- the biocompatible carrier may include at least one biocompatible adhesive such as a fibrin adhesive.
- the biocompatible carrier may include a biocompatible gel selected from a starch gel, an agarose gel, a polyacrylamide gel and a combination thereof.
- the apparatus includes an implant having a first and a second layer.
- the second layer can include at least one bioactive agent such as a growth factor as described elsewhere herein.
- the at least one bioactive agent may be a bioactive peptide.
- a method of forming an implant for repairing a tissue defect includes providing a substrate having shape memory, forming the substrate into a mold of a tissue defect of a subject, wherein the mold substantially conforms to contours of at least a portion of the tissue defect, removing the mold from the tissue defect, and disposing in the mold a composition comprising at least one biological agent and a biocompatible carrier, thereby forming the implant having a shape substantially conforming to the contours of at least the portion of the tissue defect.
- the at least one biological agent can be a pharmaceutical compound.
- the biological agent is for example a plurality of tissue particles such as cartilage particles.
- the cartilage tissue particles may be neocartilage particles, juvenile cartilage particles, cadaver cartilage particles, or may be selected from among bone tissue particles, liver tissue particles, renal tissue particles, neuronal tissue particles, muscle tissue particles, adipose tissue particles, and a combination thereof.
- the method may further comprise mixing within the mold at least one bioactive agent.
- the bioactive agent can be a growth factor selected from among a TGF- ⁇ , a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF and an activin.
- the at least one bioactive agent may be a bioactive peptide.
- the at least one bioactive agent may be a plurality of cells which may be selected from chondrocytes, osteoblasts, mesenchymal stem cells, neuronal cells, T cells, B cells, neuronal cells, liver cells, mesenchymal stem cells, adipocytes, renal cells, lung cells or a combination thereof.
- the method may include growing the plurality of cells ex vivo.
- an implant for repairing a tissue defect of a subject includes a biological agent and a biocompatible carrier, wherein the shape of the implant substantially conforms to the contours of at least a portion of a tissue defect of a subject.
- the biological agent is for example a plurality of tissue particles such as cartilage particles.
- the cartilage tissue particles may be neocartilage particles, juvenile cartilage particles, cadaver cartilage particles, or may be selected from among bone tissue particles, liver tissue particles, renal tissue particles, neuronal tissue particles, muscle tissue particles, adipose tissue particles, and a combination thereof.
- the at least one biological agent may be a population of cells such including for example a plurality of chondrocytes, fibroblasts or tendoncytes, or a combination thereof.
- the population of cells may include a plurality of cells selected from among bone cells, liver cells, and kidney cells.
- the at least one biological agent may include a pharmaceutical compound.
- the implant includes a first layer comprising the tissue particles.
- the implant may further include at least one bioactive agent such as a growth factor or a bioactive peptide as described elsewhere herein.
- the implant may further include a second layer.
- the second layer includes for example at least one biocompatible carrier such as a biocompatible polymer.
- the second layer may further include at least one bioactive agent such as a growth factor or a bioactive peptide.
- the biocompatible carrier of the second layer may include a biocompatible polymer such as a biocompatible gel selected from among a starch gel, an agarose gel, a polyacrylamide gel and a combination thereof.
- a kit for forming an implant for repairing a tissue defect includes a pliable substrate having shape memory and which can be shaped to substantially conform to the contours of at least a portion of a tissue defect thereby serving as a mold of at least the portion of the tissue defect in a subject, a biological agent and a biocompatible carrier.
- the biological agent is for example a plurality of tissue particles such as cartilage particles or other tissue particles as described elsewhere herein.
- the tissue particles may be provided in a liquid medium and the pliable substrate material having shape memory and the biocompatible carrier are all as described elsewhere herein.
- the kit may further include at least one perforation tool such as a scalpel, an awl, a pin, a needle or a forceps for perforating the mold to remove an amount of liquid medium after introducing liquid medium to the mold.
- the kit may further include at least one absorbent pad also for removing liquid medium.
- the kit may also further include at least one biocompatible adhesive such as a fibrin adhesive and may include at least one bioactive agent as described elsewhere herein.
- the kit may further an amount of calcium chloride.
- FIG. 1 is a flow diagram illustrating a method for repairing tissue defects according to the present teachings
- FIG. 2 illustrates an aluminum foil mold of the present teachings
- FIG. 3 illustrates formation of an implant in a mold of the present teachings
- FIG. 4 illustrates application of an implant of the present teachings to a cartilage defect.
- the present inventors disclose herein molds and implants for repairing tissue defects, as well as methods of forming such molds and implants, and kits for forming and using the molds and implants.
- these methods comprise forming, on a tissue defect of a subject, a mold having a surface substantially conforming to contours of a tissue defect.
- a tissue defect is, for example, a cartilage tissue defect such as an injury to a hyaline cartilage comprised by a subject, for example a torn knee cartilage.
- the tissue defect may alternatively be in any bodily tissue susceptible to repair or treatment of the defect using an implant, including musculoskeletal hard and soft tissues, oral and maxillofacial tissues, dermal tissues, and solid organ tissues.
- cartilage tissue for illustrative purposes only and should not be taken as limiting the present mold, implant and related methods of making and using to cartilage tissue alone. It is contemplated that the present mold, implant and related methods of making and using will be comparably useful in repairing or treating other hard and soft bodily tissues.
- a mold can be made of a pliable substrate material having shape memory, such as, without limitation, a polymer or a metal foil such as aluminum foil, a wax or other malleable material capable of retaining a particular shape
- the substrate material may alternatively be a liquid or fluid material such as a hydrogel or a wax in liquid phase capable of transitioning to a solid phase upon a triggering event such as exposure to a chemical agent or exposure to a change in temperature.
- a hydrogels which have a fluid phase that transitions to a solid or semi-solid phase upon exposure to a cross-linking agent. Wax in liquid phase can be disposed in the mold and then the combination cooled so that the wax resolidifies.
- suitable substrate materials include those having the ability to adapt or conform to at the three-dimensional configuration of at least a portion of a tissue defect, and then to return to the shape conformation if briefly deformed upon removal from the defect after conforming thereto.
- the substrate may be a material permeable to liquid, such as liquid that may be part of a liquid storage medium for cells or tissue.
- a medical caregiver such as a physician or surgeon can manually, with or without a surgical instrument, press the foil on to a tissue defect, such that the substrate material is substantially juxtaposed to contours of the defect (see examples below).
- a substrate material such as a foil can initially be sterile (e.g., as a result of autoclaving), and initially can be substantially flat.
- a foil can be of any available thickness and any convenient initial size and shape, such as, in non-limiting example, a square or rectangle of from about 5 cm to about 10 cm a side, or a circle of about 5 cm to about 10 cm diameter.
- a mold substrate such as a metal foil can have a thickness of from about 5 microns to about 200 microns; from about 10 microns to about 100 microns, from about 12 microns to about 30 microns, or from about 13 microns to about 25 microns.
- the mold after a foil is molded to a tissue defect, the mold can have contours corresponding to those of the defect; it can further comprise walls that can aid in keeping added materials within the mold during formation of an implant.
- a polymer such as a pliable plastic (such as a putty) can provide the substrate material for forming a mold.
- a medical caregiver such as a physician or surgeon can manually or otherwise mechanically using surgical instruments press the plastic on to the defect, such that the plastic is substantially juxtaposed to contours of the defect.
- the material can be flattened by methods known to persons of skill in the art prior to application of the material to a tissue defect.
- an amount of a pliable solid substrate material such as a metal foil, meshed metal or plastic can initially be configured in a compact folded or pleated configuration for delivery to the site of the defect in vivo, and then mechanically expanded and applied to the defect site in order to conform thereto.
- an amount of a pliable solid substrate material such as a metal foil may be configured in a “pleated skirt” configuration or any other folded or pleated configuration that achieves sufficient compaction of the material for it to be delivered to the defect site in vivo through limited access routes, for example using laparoscopic surgical catheters, and then expanded at the defect site so that it may be applied and conform to the defect site.
- a curable plastic or other suitable liquid material such as a wax or a hydrogel can be applied to a tissue defect as a liquid, e.g. by flowing through a syringe.
- a curable plastic can be, for example, a polyurethane described in U.S. Pat. No. 6,443,988 to Felt et al., or an epoxide plastic in which a monomer is mixed with a catalyst prior to applying to applying to a tissue defect, and which polymerizes while in contact with the defect.
- a plastic can be a bioabsorbable polymer, such as a polyester.
- a polyester can comprise a polylactic acid, a polyglycolic acid, and/or a co-polymer comprising a polylactic acid and a polyglycolic acid.
- the mold following formation of the mold which has contours substantially conforming to the contours of a tissue defect, the mold is removed from the defect. Removal is accomplished manually, or otherwise mechanically with the aid of tools or surgical instruments such as forceps, or may be accomplished or assisted by exposure to a chemical or physical stimulus. For example, exposure to an increase in temperature can be used to accomplish or assist removal of a wax mold by partially melting the mold to the point that the mold is released from the implant. Alternatively, in the case of certain hydrogels, exposure to a chemical agent such as a cationic composition can break bonds between the mold and the implant. Because the mold comprises a substrate material having shape memory, if the mold is deformed during removal from the tissue defect, the mold regains the contours of the defect upon which it was formed. An implant can then be formed within the mold ex vivo.
- formation of the implant is accomplished by introducing into the mold a suitable biological agent such as tissue particles, cells, collagen, extracellular matrix (ECM) or tissue-engineered scaffold material.
- the biological agent can be cartilage particles such as those described in U.S. Patent application publication 2005152882 (application Ser. No. 11/010,779 of Kizer et al., filed Dec. 13, 2004).
- the choice of what type of biological agent to use for forming the implant for a particular application may take into account, for example, whether a need exists for a longer shelf-life for the implant once formed.
- Use of tissue-engineered scaffold for forming the implant may be especially well-suited for applications where it is anticipated that the implant will remain in storage for a period of time.
- the scaffolding may later be populated with cells just before or at about the time the implant is being prepared for actual implantation.
- tissue particles or other biological agents or both are added to the mold along with liquid medium in which the particles or other agents are carried or suspended and maintained. Excess liquid medium can then be removed from the mold by aspiration, or, in some configurations, by piercing the mold to introduce one or more apertures so that the liquid can drain, or by a combination of aspiration and piercing.
- perforations can be introduced to the mold using any sharp tool or implement, such as, without limitation, a scalpel, a forceps, a needle, a pin or an awl.
- the mold is formed of a substrate material that is perforated or is a mesh material that does not require additional piercing or perforation for draining excess liquid medium.
- the mold is formed of a substrate material that is otherwise permeable to liquid, such as a porous or semi-porous membrane, so that when tissue particles or cells in a liquid storage medium are introduced to the mold, excess liquid medium drains through the material without the need for perforations.
- draining of liquid through perforations or mesh material can be promoted by contacting the mold with an absorbent body, such as, without limitation, a surgical sponge, paper towel, gauze or pad.
- an absorbent body such as, without limitation, a surgical sponge, paper towel, gauze or pad.
- the tissue particles or other biological agent for forming the implant may be disposed in the mold without excess liquid medium.
- excess liquid medium may be removed from tissue particles or other biological agent prior to disposing in the mold.
- the tissue particles or other biological agent may not have required combination with excess liquid medium in the first instance in order to be suitable for disposition in the mold. In either case, it will be appreciated that while excess liquid medium may assist in achieving a more uniform distribution of the tissue particles or other biological agent in the mold, excess liquid is not necessarily required for the distribution to be sufficient for formation of the implant.
- autologous tissue that has been removed from the subject may be especially suitable for forming the implant, and such tissue may exist in a form such as a tissue core or plug reasonably well-suited to being disposed in the mold without the need to add liquid medium.
- a biocompatible carrier is added to the mold.
- the carrier is added to the mold before, during or after adding the biological agent such as tissue particles, cells, collagen, ECM or a tissue-engineered scaffold.
- a carrier can be added to a mold as a liquid.
- Such a carrier can embed the one or more tissue particles, and can also form a solid.
- a liquid carrier can fill space within the mold and therefore can have a shape substantially conforming to the contours of the mold.
- a carrier can be a biological adhesive such as a fibrin glue.
- fibrin glue include fibrin generators such as mixtures of fibrinogen and thrombin (Gibble, J W and Ness, P M, Transfusion 30: 741-747,1990; Alston, S et al., Translational Research 149: 187-195, 2007).
- a fibrin glue can be a commercially available fibrin glue such as Tisseel® VH fibrin sealant (Baxter Healthcare Corporation, Westlake Village, Calif.), which can be prepared for use according to manufacturer's instructions.
- a biocompatible carrier can comprise at least one biocompatible polymer, such as, without limitation, a fibrinogen, a thrombin, a fibrin, a type I collagen, a type II collagen, a type III collagen, a gelatin, a fibronectin, a laminin, a hyaluronic acid, a hydrogel, a pegylated hydrogel, a chitosan or a combination thereof.
- a biocompatible polymer can be autologous to the intended recipient of an implant, and can be, without limitation, an autologous plasma protein such as autologous thrombin, autologous fibrinogen, autologous fibrin and/or autologous fibronectin.
- a biocompatible carrier can comprise a biocompatible gel, which can be, without limitation, a starch gel, an agarose gel, a polyacrylamide gel or a combination thereof.
- a biological agent such as tissue particles within a mold can be arranged such that the particles are distributed substantially uniformly within the mold.
- instruments and tools such as forceps and needles can be used to arrange the particles.
- the particles and the carrier can together comprise a first layer, within which the particles can be distributed substantially uniformly.
- the carrier can congeal, thereby forming an implant having contours substantially corresponding to those of the mold and hence to a tissue defect.
- the distributing can be effected before or after removal of the liquid, or after addition of a biocompatible carrier (see below).
- a biological agent such as tissue particle
- a biocompatible carrier such as a fibrin glue
- an implant or a first layer thereof can comprise particles which are immobilized and distributed substantially uniformly throughout a biocompatible carrier.
- a second or additional layer can be formed in a mold. Such a layer can be added adjacent to a first layer, for example, by adding a layer of fibrin glue over a previously formed layer comprising fibrin glue and tissue particles.
- a second or additional layer can comprise components which are the same or different from those of the first layer.
- a second or additional layer can comprise at least one biocompatible carrier.
- a second layer can also comprise one or more bioactive agents such as one or more growth factors, one or more bioactive peptides, and/or cell populations.
- a second layer can comprise a biocompatible gel, and/or tissue particles such as cartilage tissue particles.
- the implant and the mold can be separated in various aspects. Separation can be effected using methods well known to skilled artisans and will depend in part on the material used for the mold. For example, one or more slits can be made in a mold with a scalpel, and pieces of the mold can be pulled away from the implant with the aid of forceps. In some aspects, such as with a mold made of pre-perforated material, the mold may be torn or peeled away from the implant with or without the aid of a surgical instrument. In the case of a mold made of a wax for example, the mold may be melted for removal. In other aspects, certain mold materials such as for example hydrogels may be readily susceptible to being dissolved away using a chemical agent. It is further contemplated that other physical methods and tools such as those involving laser or electrocautery may be sued to remove the mold from the implant.
- an implant can be flexible yet resilient to deformation, so that it can return substantially to its original shape following a deformation, for example after passaging through a hollow needle. Following separation of an implant from a mold, the implant can be applied to the tissue defect.
- a method can further include affixing the implant to the tissue defect.
- affixing an implant can include securing the implant to the tissue defect using methods and materials well known to skilled artisans such as, for example, biocompatible glues, sutures, staples, or pins.
- a biological glue can be used to affix an implant to a tissue defect after the contours of the implant are apposed to the corresponding contours of the defect.
- a mold can comprise a bioabsorbable substrate material such as a polyester.
- a mold formed at the site of a defect in vivo may also be withdrawn from the defect site, for example through a hollow needle, and upon returning substantially to its original shape following deformation, is then used ex vivo for formation of the implant.
- the mold and implant are then together introduced to the defect site through the hollow needle and together applied to the defect site.
- a combination of mold and implant can be applied to a tissue defect without separating the mold from the implant.
- an implant in aspects in which an implant is deformable, can be administered to a subject by injecting the implant into the subject at the site of the tissue defect using a syringe and a hypodermic needle.
- the mold can be separated from the implant by standard surgical procedures known to skilled artisans, such as, without limitation, slicing of the mold followed by removal of the mold from the defect.
- tissue particles can be initially carried or suspended in a liquid medium.
- a liquid medium is, in various aspects, a cell, tissue or organ storage medium, such as, without limitation, a medium disclosed in U.S. Patent application publication 2005152882 (the disclosure of which is herein incorporated by reference in its entirety), for example Dulbecco's Modified Eagle's Medium (DMEM) or Roswell Park Memorial Institute Medium (RPMI).
- DMEM Dulbecco's Modified Eagle's Medium
- RPMI Roswell Park Memorial Institute Medium
- an implant and/or a mold of the present teachings can further comprise at least one bioactive agent, such as, without limitation, a hormone, a growth factor, a pharmaceutical compound, a bioactive peptide, a nucleotide such as an RNAi molecule, a vector, a plurality of cells, and the like.
- the bioactive agent can be a constituent of any layer of an implant.
- a growth factor can be, without limitation, a TGF- ⁇ , a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF or an activin.
- a pharmaceutical compound can be, without limitation, an analgesic, an anesthetic such as a local anesthetic, or a cyclooxygenase inhibitor.
- a bioactive peptide can be, without limitation, neuropeptide Y, secretin, cholecystokinin, or a cell-penetrating peptide such as penetratin, substance P or R 9 or for example any bioactive peptide with antimicrobial activity.
- a bioactive agent can comprise a plurality of cells.
- Such cells can be, without limitation, chondrocytes, osteoblasts, mesenchymal stem cells, neuronal cells, T cells, B cells, neuronal cells, liver cells, mesenchymal stem cells, adipocytes, renal cells, lung cells and combinations thereof.
- the cells can be autologous to an intended recipient of an implant, and can be obtained directly from the intended recipient or grown in vitro prior to adding to an implant.
- the bioactive agent may comprise a nucleotide.
- a nucleotide can be a naturally occurring sequence of DNA or RNA, synthetic DNA or RNA, or chemically modified DNA or RNA, such as chemically modified otherwise naturally occurring RNAi molecules.
- the bioactive agent may comprise a vector, for example for introducing a genetic sequence to the implant.
- a vector can be for example a viral vector.
- a subject can be a mammal, which can be a human or a non-human mammal.
- a human subject can be a human in need of treatment of a tissue defect, such as a cartilage defect.
- a human subject can have a degenerate or damaged cartilage such as a hyaline cartilage comprised by a joint.
- a mold and an implant formed therein can be three dimensional, such as when its shape corresponds to the contours of a tissue defect.
- the present teachings provide implants which are not limited to two-dimensional structures, such as films or laminates.
- a mold and implant formed therein can be substantially cylindrical in shape, such as, without limitation, when a tissue defect such as a cartilage defect is prepared by a surgeon to include a substantially cylindrical aperture.
- a caregiver such as a surgeon can, prior to forming a mold, prepare a tissue defect such as a cartilage defect for receiving an implant by removing tissue from the defect, such that a circular or cylindrical defect remains.
- the methods can include preparing a tissue defect for receiving an implant.
- the preparation can comprise modifying the defect to comprise a substantially cylindrical aperture.
- an advantage of the present mold, implant and related methods and kits is the ability to adapt the shape of the mold and ultimately the shape of the implant to any shape that helps repair the defect while also preserving the greatest amount of healthy tissue.
- the site-specific mold and implant can avoid the need to remove healthy tissue to adapt the shape of the defect to a particular predetermined shape of the implant.
- the present mold, implant, related methods and kits are well-suited for use in a “tiling” approach using multiple implants at a defect site.
- a biological agent can comprise a plurality of tissue particles, such as cartilage particles.
- a biological agent can comprise a population of cells.
- a population of cells of these embodiments can comprise, without limitation, a population of chondrocytes, a population of fibroblasts, a population of tendoncytes, a population of bone cells such as osteoblasts, a population of kidney cells, a population of lymphocytes such as T lymphocytes or B lymphocytes, a population of hepatocytes, and/or a population of stem cells such as mesenchymal stem cells or embryonic stem cells, or a combination of any such cell populations.
- the inserting and the affixing of an implant to a tissue defect can be accomplished using methods well known to skilled artisans, such as inserting the implant using a minimally invasive surgical technique (MIS), such as arthroscopically.
- MIS minimally invasive surgical technique
- An MIS for example, includes a mini-open arthrotomy with minimal disruption of the surrounding joint structure, typically involving a smaller incision than incisions required in regular open cartilage repair surgeries.
- the present mold, implant and related methods of forming and using same contemplate their application in situations involving defects to bone tissue underlying all or a portion of the tissue defect, for example the cartilage tissue defect.
- alternative materials such as engineered bone tissue and/or trabecular metal may be used to reconstruct a bone tissue defect underlying a cartilage tissue defect.
- FIG. 1 is a flow diagram illustrating the steps in a method 100 for repairing tissue defects according to the present teachings.
- the method provides implants that are very well fit to the specific tissue defect.
- a surgeon, technician or other individual trained in orthopedic surgical techniques applies the substrate material having shape memory, to all or a portion of the tissue defect to be repaired.
- the tissue defect is, for example, a cartilage tear in a major joint such as the knee.
- the mold is prepared in vivo in the subject having the tissue defect.
- the process of applying the substrate material to all or a portion of the tissue defect for example by manually pressing with or without aid of a surgical instrument, conforms 102 the substrate material to the contours of the tissue defect or portion thereof.
- a wait period (not itemized in FIG. 1 ) may be required in order to allow the substrate material to undergo processes necessary for the material to retain the contours of the tissue defect or portion thereof to which the substrate material has been applied.
- the substrate material is a curable plastic or polymerizing plastic
- Commercially available epoxies and other curable or polymerizing plastics for such purposes are well known and should be used according to manufacturer's instructions for the process of curing or polymerizing.
- the substrate material being used is a metal foil
- the foil immediately retains the geometry of the tissue defect to which it has been firmly applied.
- the individual preparing the mold ascertains that the substrate material has attained sufficient shape memory of the tissue defect or portion thereof, the individual removes 103 the mold from the tissue defect, typically by simply using gloved fingers or with a sterile surgical instrument.
- the implant will be formed ex vivo using the mold formed in vivo.
- the implant material includes at least a biological agent such as tissue particles.
- the tissue particles e.g. cartilage particles, may be further maintained in a liquid medium as described elsewhere herein.
- the liquid medium can facilitate delivery of the tissue particles into the mold. If a liquid medium is used, it is removed from the mold by aspiration, or by piercing or perforating the mold to drain the liquid after the tissue particles are placed in the mold.
- the substrate material is perforated to start with, or is a mesh type material sufficient to initially receive an implant material including a liquid constituent, and then to allow the liquid constituent to drain from the mold after a short period of time during which the implant material is distributed within the mold.
- a biocompatible carrier is also added to the mold to form a first layer of the implant.
- the biocompatible carrier may be added to the mold before, during or after placing the tissue particles in the mold.
- fibrin can be combined directly with cartilage tissue particles with or without medium.
- forming the mold may also include adding a bioactive agent or agents to the mold, thereby forming another layer of the implant, or as part of the first layer.
- adding a bioactive agent or agents may include adding growth factors or hormones, pharmaceutical compounds, bioactive peptides, nucleotides, vectors, or other cells.
- the implant is separated from the mold 106 , and the implant is applied 107 to the tissue defect or portion thereof to which the implant now conforms.
- the implant may be applied to the tissue defect together with the mold first, and the mold then separated from the implant after implantation, or the mold may be removed from the implant before the implant is applied to the tissue defect.
- the implant comprising at least the tissue particles and a biocompatible carrier, is made contour-specific for the particular tissue defect and therefore very well fit to the tissue defect. It is believed that the high fit specificity of the implant improves recovery speed and outcomes.
- kits for forming the aforementioned mold and implant for repairing a tissue defect encompass a kit for forming the aforementioned mold and implant for repairing a tissue defect.
- the mold materials and implant materials may be advantageously provided in kit form including separately packaged amounts of each type of material.
- the amounts of each material can be for example amounts sufficient for the treatment or repair of a defect of a predetermined size.
- a kit includes an amount of the pliable substrate for forming the mold as described herein, and the biological agent such as a plurality of cells or tissue particles.
- the kit may further comprise an amount of the biocompatible carrier.
- a kit can include an amount of the pliable substrate and an amount of the carrier, with the biological agent such as tissue particles or cells to be provided from another source.
- each component of the kit is packaged separately in sterile packaging or in packaging susceptible to sterilization.
- the biological agent such as cells or tissue particles may be in a container such as a glass or plastic vial and may further be carried or suspended in a liquid storage medium suitable for maintaining cells, tissues or organs.
- the kits may further include an absorbent material in the form for example of a pad or wipe for absorbing excess liquid medium from the mold after the biological agent has been introduced to the mold.
- the pliable substrate can be wrapped or sealed separately in a paper or plastic wrapper, sterilized blister pack or the like.
- the biocompatible carrier for example fibrin, can also be contained in a separate glass or plastic vial or other compact container.
- the kit may optionally further include one or more syringes or other delivery device(s) for introducing the implant material and carrier to the mold.
- Kits may optionally further include one or more additional containers each storing a bioactive agent such as growth factor or a pharmaceutical agent that may be added to the implant.
- the kit further includes, for example, printed instructions for forming the mold and the implant and for using the implant to repair a tissue defect. All elements of the kit are provided together in suitable amounts in a box or other suitable packaging.
- This example illustrates formation of a mold.
- a sterile piece of aluminum foil having sufficient moldability and rigidity is applied by physician to a cartilage injury.
- the physician uses her fingers or a surgical instrument such as a spatula to press the aluminum foil into the cartilage defect so that the foil is in extensive contact with the base and side walls of the defect.
- This shaping results in a mold which can be used to form an implant which matches the size and shape of the defect ( FIG. 1 ).
- This example illustrates formation of an implant of the present teachings using a mold.
- a syringe is used to transfer cartilage tissue fragments and storage medium to the base of an aluminum foil mold of a cartilage defect, such as the mold illustrated in Example 1.
- Excess fluid is removed by aspiration, and also by introducing holes in the base of the mold using a scalpel.
- the mold is contacted with an absorbent sterile pad to absorb liquid through the holes.
- the pieces distribute evenly across the surface of the base of the foil mold.
- a layer of fibrin is then gently added to embed the cartilage particles within the mold. More fibrin is then overlaid on the first layer to increase the thickness of the implant.
- the skirt of the foil mold is then gently pulled to straighten the foil, or pulled or peeled away using a surgical instrument such as a forceps This action releases the implant from the foil mold, which is now available for implantation at a cartilage defect.
- This example illustrates formation of an implant in an alternative aspect of the present teachings.
- Example 2 above describes formation of a implant using a multiple step process including first the introduction of cartilage tissue fragments to the mold followed by introduction of fibrin to the mold.
- an implant is formed in a “single-step” process.
- Cartilage tissue fragments are combined with fibrin and the combination is introduced to the mold, also using a syringe.
- a pharmaceutical agent such as a growth factor is optionally added to the combination before introducing the combination the mold.
- This approach is well-suited for carrier materials that have a well-defined and predictable setting time.
- This example illustrates transfer of an implant to a tissue defect.
- a cartilage defect in a cadaver is exposed.
- a fibrin adhesive is applied to the base of the cartilage defect, and the implant of Example 2 is gently lifted with a spatula and placed into the defect such that contours of the defect and the implant correspond ( FIG. 3 ).
- the implant is then gently pressed against the defect and pulled with forceps so that the implant fits snugly in the defect.
- more fibrin is then added around and over the implant to fill the defect to the extent needed.
- This example illustrates transfer of an implant to a tissue defect.
- a cartilage defect in a cadaver is exposed.
- a fibrin adhesive is applied directly to the intended contact surface of the implant of Example 2, and the implant of is gently lifted with a spatula and placed into the defect such that contours of the defect and the implant bearing the previously applied layer of fibrin adhesive correspond.
- the implant is then gently pressed against the defect and pulled with forceps so that the implant fits in the defect. More fibrin is optionally then added around and over the implant to fill the defect as may be needed.
- This example illustrates a protocol for treating a cartilage defect.
- an autologous fibrin adhesive is prepared at least one week in advance of surgery.
- a commercially prepared fibrin as obtained off the shelf.
- a medial or lateral parapatellar mini-arthrotomy is performed using a tourniquet (which need not be inflated).
- the defect area is marked with a sterile surgical marker.
- the cartilage tissue is removed within the defect area with a curette, thereby creating a well-defined vertical defect perimeter.
- the defect base is then cleared to remove the calcified cartilage layer, taking care to avoid violating the subchondral cortical bone plate. If subchondral bone bleeding occurs, it must be stopped before implantation of an implant of the present teachings.
- the defect and surrounding tissue are irrigated frequently with normal saline during the surgery.
- Sub-chondral bleeding methods for controlling and stopping subchondral bleeding include: a) use of neuro-patties soaked with a dilute 1:1000 epinephrine and sterile saline solution; b) direct application of thrombin to the site of bleeding; c) electrocautery using a needle-tipped electrocautery device to cauterize only the bleeding points, not the entire base of the defect. Electrocautery can be used, particularly if bleeding is especially difficult to control, for example in a patient who had previous marrow stimulation.
- Defect sizing with the aid of a sterile flat-ended rod, a sterile thin foil is pressed into the defect so that the outer shape of the foil fits snugly into the defect base and vertical wall.
- the approximate surface area of the defect is measured to determine the approximate amount of cartilage particles needed. If DeNovo® NT particles (Isto Technologies, Inc., St. Louis, Mo. and Zimmer, Inc., Warsaw, Ind.) are used, one pack of particles is needed for each about 0.5 to about 3.0 cm 2 defect or for an average of about 2.5 cm 2 defect.
- the foil mold is removed from the defect and placed on sterile gauze or a sterile absorbent plant.
- the defect may be documented photographically, including a ruler showing two dimensions at 90 degrees to each other.
- Implant Preparation A clear sterile piece of plastic tubing, at least 30 mm in length, is attached to a sterile syringe with a luer tip orifice of ⁇ 1 mm. The lid of a package of DeNovo® NT particles is opened, and the cartilage tissue particles and medium are aspirated using the syringe. The cartilage particles will be contained within the tubing, while the storage medium will be aspirated into the syringe barrel. The cartilage and the storage medium are transferred to the foil old. Excess storage medium is aspirated by aspiration until only a shallow pool of the medium remains. This is done so that the cartilage pieces are not clumped together.
- tissue pieces are then distributed evenly across the surface base of the foil mold with the tip of the syringe. Remaining liquid is removed by aspiration while avoiding further movement of the cartilage pieces.
- a sharp tip tool such as a scalpel is also used to make small perforations in the foil at various locations to allow excess liquid to be absorbed by an absorbent sterile gauze or pad underlying the foil mold.
- a layer of fibrin glue is then gently applied to embed the particulate tissue pieces. More fibrin is then applied, such that the tissue/fibrin composite fills to about 3 ⁇ 4 the depth of the mold. The fibrin is then set for 5-10 minutes in accordance with fibrin preparation instructions.
- the edges of the foil mold are then gently pulled to straighten the foil so that the tissue/fibrin implant separates from the vertical walls of the foil mold.
- the implant can then be lifted from the mold base using a sterile flat instrument such as a spatula. The implant is now ready for implantation.
- the implant is prepared using the single-step process in which the fibrin is added directly to the cartilage particles in the syringe tubing by aspirating the fibrin after any excess storage medium is aspirated.
- the fibrin may otherwise be added directly to the cartilage particles and medium in the tubing and syringe in the case where no excess storage medium is aspirated.
- the cartilage tissue particles together with the fibrin may be gently agitated using the action of the syringe plunger within the syringe barrel to promote gentle mixing of the fibrin with the cells and any remaining medium.
- the mixture of cartilage particles, fibrin and any remaining medium is then introduced across the surface base of the foil mold with the tip of the syringe. Remaining steps for removal and use of the implant thus formed are as described above.
- Fixation of an implant into a cartilage defect Initially, the defect area and the implant are gently dried using sterile surgical gauze. A very thin layer of fibrin glue, approx. 0.01-0.1 ml to cover then entire base of the defect. The implant is then placed on the defect, ensuring a matched fit between the contours of the defect and those of the implant. The implant is then gently held in close contact with the base and edges of the defects (e.g., using a finger). The implant should be recessed by approximately 0.5 mm relative to surrounding native cartilage. The implant is held against the defect and gently stretched (using instruments such as a pair of surgical forceps) so that the implant fits snugly to the defect wall. The fibrin is allowed to cure for at least 5 minutes, and care must be taken not to manipulate or dislodge the implant during the curing. The transfer of the implant to the defect can be documented photographically.
- drains can be inserted within the wound site.
- the joint capsule, fascial layers and skin can be closed using standard suture and surgical techniques.
Abstract
Description
- This application claims priority from U.S. Provisional Application Ser. No. 60/911,429 filed on Apr. 12, 2007, the disclosure of which is incorporated herein by reference in its entirety.
- Not Applicable.
- Not Applicable.
- The need for implants for repairing tissue defects, such as cartilage tissue defects, is ongoing. Materials have been developed to fill spaces comprising tissue defects, but have typically been two-dimensional, comprising, for example, a flat sheet cut to approximate the dimensions of a tissue defect, or a layer of cells grown in vitro, from which a two dimensional sheet of cells is applied to a tissue defect.
- U.S. Pat. No. 5,067,964 to Richmond et al. discloses an articular cartilage repair piece and methods of forming. This patent discloses a repair piece which includes a backing layer of non-woven, felted fibrous material which is conformable to flat and curved surfaces.
- U.S. Pat. Nos. 5,655,546 and 6,179,871 to Halpern disclose methods for repairing a cartilage defect, comprising the provision of apertures in the cartilage by drilling holes at the base of the cartilage defect. The holes may enter the mesenchymal depot. In these methods, a porous scaffold material containing a plurality of magnetic particles is introduced into the apertures. Subsequently and sequentially, magnetically-tagged cartilage growth promoting materials such as chondrocytes or growth factors are injected into the area of the defect.
- U.S. Pat. No. 6,443,988 to Felt et al. discloses methods and apparatuses for repairing a tissue site. The method involves use of a curable polyurethane adapted to be mixed at time of use in order to provide a flowable composition and initiate cure.
- U.S. Pat. Nos. 6,511,958 and 6,514,514 to Atkinson et al. disclose devices and products for repair of cartilage lesions, comprising a cartilage repair matrix suitable for conforming to a cartilage defect and a cartilage-inducing composition on or within the matrix.
- U.S. Pat. Nos. 6,626,945, 6,632,246 and 6,852,125 to Simon et al describe cartilage plugs made from a biocompatible artificial material. These plugs are made according to pre-determined shapes.
- The aforementioned patents do not describe a biological implant having surface contours substantially conforming to those of a tissue defect such as a cartilage defect. In view of these considerations, the present inventors have developed methods, compositions, apparatuses and kits for repairing a tissue defect such as a cartilage defect.
- In some embodiments of the present teachings, these methods comprise forming, on a tissue defect of a subject, a mold conforming to the contours of at least a portion of the tissue defect, removing the mold from the defect, forming in the mold an implant comprising one or more tissue particles and a biocompatible carrier, whereby the implant has a shape substantially conforming to the contours of at least the portion of the tissue defect, separating the implant from the mold, and applying the implant to at least the portion of the tissue defect.
- In various aspects of the method and apparatus, the mold comprises for example a pliable substrate having shape memory, which in one embodiment is a sterile substrate. The substrate having shape memory is for example a metal foil such as aluminum foil, a plastic, or a polymer such as a polyurethane or a curable plastic. The substrate may be a material permeable to liquid. The one or more tissue particles are in one embodiment initially suspended in a liquid medium which can be a cell, tissue or organ storage medium. In one embodiment, forming the implant includes removing an amount of the liquid medium from the mold. The liquid medium may be removed by introducing one or more perforations in the mold, thereby promoting draining of the liquid medium from the mold. Alternatively, the mold is made of a substrate material initially having perforations therethrough, or of a substrate material that is permeable to liquid. The liquid medium may be further removed by contacting the mold with an absorbent pad. In one embodiment the method further comprises distributing the tissue particles substantially uniformly in the mold. The biocompatible carrier can include at least one biocompatible polymer such as a fibrinogen, a fibrin, a thrombin, a type I collagen, a type II collagen, a type III collagen, a gelatin, a fibronectin, a laminin, a hyaluronic acid, a hydrogel, a pegylated hydrogel or a chitosan. The biocompatible carrier may include at least one biocompatible adhesive such as a fibrin adhesive. The implant may further comprise at least one bioactive agent such as a growth factor. The growth factor can be selected for example from among a TGF-β, a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF and an activin. The at least one bioactive agent may be a bioactive peptide.
- In one aspect, forming in the mold an implant comprises forming an implant including a first layer including the one or more tissue particles and a second layer comprising the biocompatible carrier. The second layer may further include at least one bioactive agent, which can be a growth factor which can be selected from among a TGF-β, a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF and an activin. The at least one bioactive agent in a second layer of the implant can be a bioactive peptide. In another aspect of the method, applying the implant to the tissue defect includes inserting the implant at the tissue defect. Applying the implant to the tissue defect can further comprise affixing the implant to the tissue defect. Inserting the implant at the tissue defect can include inserting the implant using a minimally invasive surgical technique, such as arthroscopically. In one embodiment, the biocompatible carrier can be a biocompatible gel, such as a starch gel, an agarose gel, a polyacrylamide gel or a combination thereof. The carrier that includes at least one biocompatible polymer may be autologous to the subject. In various aspects, the subject of treatment using the method is a non-human mammal, or is a human in need of treatment of the tissue defect. In one aspect, the contours of the tissue defect being treated are three-dimensional. In one aspect the contours of the tissue defect can be substantially cylindrical.
- In another aspect, a method of repairing a tissue defect includes forming, on a tissue defect in a subject, a mold having a surface conforming substantially to contours of the tissue defect, wherein the mold comprises a bioabsorbable substrate having shape memory, removing the mold from the tissue defect, forming within the mold an implant comprising at least a first layer, wherein the first layer comprises one or more tissue particles and a biocompatible carrier, whereby the implant has a shape substantially conforming to the contours of the tissue defect; and applying the mold and implant to the tissue defect. The bioabsorbable substrate having shape memory is sterile. The bioabsorbable substrate having shape memory is for example a plastic, which can be a bioabsorbable polymer such as a bioabsorbable polyester. The bioabsorbable polymer can be a polyester selected from among a polylactic acid, a polyglycolic acid, and a co-polymer comprising a polylactic acid and a polyglycolic acid. In one aspect, the method may further include distributing the tissue particles substantially uniformly throughout the first layer. The second layer includes for example at least one biocompatible carrier. The second layer can include at least one bioactive agent such as a growth factor.
- In another aspect a method is provided for repairing a tissue defect in a subject, which includes forming, on the tissue defect a mold having a surface substantially conforming to the contours of at least a portion of the tissue defect, removing the mold from the tissue defect, forming within the mold an implant comprising one or more tissue particles and a biocompatible carrier, whereby the implant has a shape substantially conforming to the contours of the portion of the tissue defect, applying the mold and implant together to the portion tissue defect, and separating the implant from the mold after applying to the tissue defect. Applying the implant to the tissue defect may include inserting the implant at the tissue defect and may further include affixing the implant to the tissue defect. Inserting the implant at the tissue defect may include inserting the implant using a minimally invasive surgical technique such as arthroscopically.
- In another aspect, apparatus is provided for forming an implant for repairing a tissue defect, the apparatus including a mold having a shape substantially conforming to the contours of a tissue defect of a subject, and a composition including one or more tissue particles and a biocompatible carrier, the composition disposed in the mold wherein the shape of the composition substantially conforms to the contours of the tissue defect. The mold is formed from a substrate having shape memory such as for example a metal foil such as aluminum foil, a plastic, or a polymer such as a polyurethane or a curable plastic. The substrate may be for example a sterile substrate. The substrate may be a material permeable to liquid. The substrate may be a bioabsorbable substrate having shape memory such as a bioabsorbable polymer including a bioabsorbable polyester which may be selected from a polylactic acid, a polyglycolic acid, and a co-polymer comprising a polylactic acid and a polyglycolic acid. The mold may have one or more perforations therethrough for draining excess liquid medium. The tissue particles can be cartilage tissue particles such as neocartilage particles, juvenile cartilage particles, cadaver cartilage particles, or may be selected from among bone tissue particles, liver tissue particles, renal tissue particles, neuronal tissue particles, muscle tissue particles, adipose tissue particles, and a combination thereof. The apparatus includes in some aspects the tissue particles distributed substantially uniformly in the mold. The biocompatible carrier may include at least one biocompatible adhesive such as a fibrin adhesive. The biocompatible carrier can include at least one biocompatible polymer such as a fibrinogen, a fibrin, a thrombin, a type I collagen, a type II collagen, a type III collagen, a gelatin, a fibronectin, a laminin, a hyaluronic acid, a hydrogel, a pegylated hydrogel or a chitosan. A biocompatible polymer may be autologous to the subject. The biocompatible carrier may include at least one biocompatible adhesive such as a fibrin adhesive. The biocompatible carrier may include a biocompatible gel selected from a starch gel, an agarose gel, a polyacrylamide gel and a combination thereof. In one aspect, the apparatus includes an implant having a first and a second layer. The second layer can include at least one bioactive agent such as a growth factor as described elsewhere herein. The at least one bioactive agent may be a bioactive peptide.
- In another aspect, a method of forming an implant for repairing a tissue defect includes providing a substrate having shape memory, forming the substrate into a mold of a tissue defect of a subject, wherein the mold substantially conforms to contours of at least a portion of the tissue defect, removing the mold from the tissue defect, and disposing in the mold a composition comprising at least one biological agent and a biocompatible carrier, thereby forming the implant having a shape substantially conforming to the contours of at least the portion of the tissue defect. The at least one biological agent can be a pharmaceutical compound. The biological agent is for example a plurality of tissue particles such as cartilage particles. The cartilage tissue particles may be neocartilage particles, juvenile cartilage particles, cadaver cartilage particles, or may be selected from among bone tissue particles, liver tissue particles, renal tissue particles, neuronal tissue particles, muscle tissue particles, adipose tissue particles, and a combination thereof. The method may further comprise mixing within the mold at least one bioactive agent. The bioactive agent can be a growth factor selected from among a TGF-β, a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF and an activin. The at least one bioactive agent may be a bioactive peptide. The at least one bioactive agent may be a plurality of cells which may be selected from chondrocytes, osteoblasts, mesenchymal stem cells, neuronal cells, T cells, B cells, neuronal cells, liver cells, mesenchymal stem cells, adipocytes, renal cells, lung cells or a combination thereof. The method may include growing the plurality of cells ex vivo.
- In another aspect, an implant for repairing a tissue defect of a subject includes a biological agent and a biocompatible carrier, wherein the shape of the implant substantially conforms to the contours of at least a portion of a tissue defect of a subject. The biological agent is for example a plurality of tissue particles such as cartilage particles. The cartilage tissue particles may be neocartilage particles, juvenile cartilage particles, cadaver cartilage particles, or may be selected from among bone tissue particles, liver tissue particles, renal tissue particles, neuronal tissue particles, muscle tissue particles, adipose tissue particles, and a combination thereof. The at least one biological agent may be a population of cells such including for example a plurality of chondrocytes, fibroblasts or tendoncytes, or a combination thereof. The population of cells may include a plurality of cells selected from among bone cells, liver cells, and kidney cells. The at least one biological agent may include a pharmaceutical compound. In one aspect the implant includes a first layer comprising the tissue particles. The implant may further include at least one bioactive agent such as a growth factor or a bioactive peptide as described elsewhere herein. The implant may further include a second layer. The second layer includes for example at least one biocompatible carrier such as a biocompatible polymer. The second layer may further include at least one bioactive agent such as a growth factor or a bioactive peptide. The biocompatible carrier of the second layer may include a biocompatible polymer such as a biocompatible gel selected from among a starch gel, an agarose gel, a polyacrylamide gel and a combination thereof.
- In another aspect, a kit for forming an implant for repairing a tissue defect includes a pliable substrate having shape memory and which can be shaped to substantially conform to the contours of at least a portion of a tissue defect thereby serving as a mold of at least the portion of the tissue defect in a subject, a biological agent and a biocompatible carrier. The biological agent is for example a plurality of tissue particles such as cartilage particles or other tissue particles as described elsewhere herein. The tissue particles may be provided in a liquid medium and the pliable substrate material having shape memory and the biocompatible carrier are all as described elsewhere herein. The kit may further include at least one perforation tool such as a scalpel, an awl, a pin, a needle or a forceps for perforating the mold to remove an amount of liquid medium after introducing liquid medium to the mold. The kit may further include at least one absorbent pad also for removing liquid medium. The kit may also further include at least one biocompatible adhesive such as a fibrin adhesive and may include at least one bioactive agent as described elsewhere herein. The kit may further an amount of calcium chloride.
-
FIG. 1 is a flow diagram illustrating a method for repairing tissue defects according to the present teachings; -
FIG. 2 illustrates an aluminum foil mold of the present teachings; -
FIG. 3 illustrates formation of an implant in a mold of the present teachings; and -
FIG. 4 illustrates application of an implant of the present teachings to a cartilage defect. - The following examples are provided for illustrative purposes only and are not to be construed as limiting the invention's scope in any manner. The description of an article, a composition, or a method in an example does not imply that the described article or composition has, or has not, been produced, or that that the described method has, or has not, been performed, regardless of verb tense. The methods and compositions described throughout this specification utilize laboratory techniques well known to skilled artisans and can be found in commonly available laboratory manuals describing for example use of biomolecules, cell culture and handling techniques, and use of antibodies.
- The present inventors disclose herein molds and implants for repairing tissue defects, as well as methods of forming such molds and implants, and kits for forming and using the molds and implants.
- In various embodiments of the present teachings, these methods comprise forming, on a tissue defect of a subject, a mold having a surface substantially conforming to contours of a tissue defect. In one embodiment, a tissue defect is, for example, a cartilage tissue defect such as an injury to a hyaline cartilage comprised by a subject, for example a torn knee cartilage. The tissue defect may alternatively be in any bodily tissue susceptible to repair or treatment of the defect using an implant, including musculoskeletal hard and soft tissues, oral and maxillofacial tissues, dermal tissues, and solid organ tissues. In the following detailed description, it should be understood that reference is made to cartilage tissue for illustrative purposes only and should not be taken as limiting the present mold, implant and related methods of making and using to cartilage tissue alone. It is contemplated that the present mold, implant and related methods of making and using will be comparably useful in repairing or treating other hard and soft bodily tissues.
- In various configurations, a mold can be made of a pliable substrate material having shape memory, such as, without limitation, a polymer or a metal foil such as aluminum foil, a wax or other malleable material capable of retaining a particular shape The substrate material may alternatively be a liquid or fluid material such as a hydrogel or a wax in liquid phase capable of transitioning to a solid phase upon a triggering event such as exposure to a chemical agent or exposure to a change in temperature. For example, certain hydrogels are known which have a fluid phase that transitions to a solid or semi-solid phase upon exposure to a cross-linking agent. Wax in liquid phase can be disposed in the mold and then the combination cooled so that the wax resolidifies. It should be understood that in describing suitable pliable substrate materials as having shape memory, suitable substrate materials include those having the ability to adapt or conform to at the three-dimensional configuration of at least a portion of a tissue defect, and then to return to the shape conformation if briefly deformed upon removal from the defect after conforming thereto. The substrate may be a material permeable to liquid, such as liquid that may be part of a liquid storage medium for cells or tissue.
- In the case of a metal foil, a medical caregiver such as a physician or surgeon can manually, with or without a surgical instrument, press the foil on to a tissue defect, such that the substrate material is substantially juxtaposed to contours of the defect (see examples below). In various configurations, a substrate material such as a foil can initially be sterile (e.g., as a result of autoclaving), and initially can be substantially flat. A foil can be of any available thickness and any convenient initial size and shape, such as, in non-limiting example, a square or rectangle of from about 5 cm to about 10 cm a side, or a circle of about 5 cm to about 10 cm diameter. In various configurations, a mold substrate such as a metal foil can have a thickness of from about 5 microns to about 200 microns; from about 10 microns to about 100 microns, from about 12 microns to about 30 microns, or from about 13 microns to about 25 microns. In some configurations, after a foil is molded to a tissue defect, the mold can have contours corresponding to those of the defect; it can further comprise walls that can aid in keeping added materials within the mold during formation of an implant.
- In some aspects, a polymer such as a pliable plastic (such as a putty) can provide the substrate material for forming a mold. In these cases a medical caregiver such as a physician or surgeon can manually or otherwise mechanically using surgical instruments press the plastic on to the defect, such that the plastic is substantially juxtaposed to contours of the defect. If necessary, the material can be flattened by methods known to persons of skill in the art prior to application of the material to a tissue defect. Alternatively, an amount of a pliable solid substrate material such as a metal foil, meshed metal or plastic can initially be configured in a compact folded or pleated configuration for delivery to the site of the defect in vivo, and then mechanically expanded and applied to the defect site in order to conform thereto. For example, an amount of a pliable solid substrate material such as a metal foil may be configured in a “pleated skirt” configuration or any other folded or pleated configuration that achieves sufficient compaction of the material for it to be delivered to the defect site in vivo through limited access routes, for example using laparoscopic surgical catheters, and then expanded at the defect site so that it may be applied and conform to the defect site.
- In other aspects, a curable plastic or other suitable liquid material such as a wax or a hydrogel can be applied to a tissue defect as a liquid, e.g. by flowing through a syringe. A curable plastic can be, for example, a polyurethane described in U.S. Pat. No. 6,443,988 to Felt et al., or an epoxide plastic in which a monomer is mixed with a catalyst prior to applying to applying to a tissue defect, and which polymerizes while in contact with the defect. In yet other examples, a plastic can be a bioabsorbable polymer, such as a polyester. In various configurations, a polyester can comprise a polylactic acid, a polyglycolic acid, and/or a co-polymer comprising a polylactic acid and a polyglycolic acid.
- In an illustrative embodiment, following formation of the mold which has contours substantially conforming to the contours of a tissue defect, the mold is removed from the defect. Removal is accomplished manually, or otherwise mechanically with the aid of tools or surgical instruments such as forceps, or may be accomplished or assisted by exposure to a chemical or physical stimulus. For example, exposure to an increase in temperature can be used to accomplish or assist removal of a wax mold by partially melting the mold to the point that the mold is released from the implant. Alternatively, in the case of certain hydrogels, exposure to a chemical agent such as a cationic composition can break bonds between the mold and the implant. Because the mold comprises a substrate material having shape memory, if the mold is deformed during removal from the tissue defect, the mold regains the contours of the defect upon which it was formed. An implant can then be formed within the mold ex vivo.
- In one embodiment, formation of the implant is accomplished by introducing into the mold a suitable biological agent such as tissue particles, cells, collagen, extracellular matrix (ECM) or tissue-engineered scaffold material. For example, the biological agent can be cartilage particles such as those described in U.S. Patent application publication 2005152882 (application Ser. No. 11/010,779 of Kizer et al., filed Dec. 13, 2004). The choice of what type of biological agent to use for forming the implant for a particular application may take into account, for example, whether a need exists for a longer shelf-life for the implant once formed. Use of tissue-engineered scaffold for forming the implant may be especially well-suited for applications where it is anticipated that the implant will remain in storage for a period of time. The scaffolding may later be populated with cells just before or at about the time the implant is being prepared for actual implantation.
- In various embodiments, tissue particles or other biological agents or both are added to the mold along with liquid medium in which the particles or other agents are carried or suspended and maintained. Excess liquid medium can then be removed from the mold by aspiration, or, in some configurations, by piercing the mold to introduce one or more apertures so that the liquid can drain, or by a combination of aspiration and piercing. In various configurations, perforations can be introduced to the mold using any sharp tool or implement, such as, without limitation, a scalpel, a forceps, a needle, a pin or an awl. In other embodiments, the mold is formed of a substrate material that is perforated or is a mesh material that does not require additional piercing or perforation for draining excess liquid medium. Alternatively, the mold is formed of a substrate material that is otherwise permeable to liquid, such as a porous or semi-porous membrane, so that when tissue particles or cells in a liquid storage medium are introduced to the mold, excess liquid medium drains through the material without the need for perforations.
- In some aspects, draining of liquid through perforations or mesh material can be promoted by contacting the mold with an absorbent body, such as, without limitation, a surgical sponge, paper towel, gauze or pad.
- In other aspects, the tissue particles or other biological agent for forming the implant may be disposed in the mold without excess liquid medium. For example, excess liquid medium may be removed from tissue particles or other biological agent prior to disposing in the mold. Alternatively, the tissue particles or other biological agent may not have required combination with excess liquid medium in the first instance in order to be suitable for disposition in the mold. In either case, it will be appreciated that while excess liquid medium may assist in achieving a more uniform distribution of the tissue particles or other biological agent in the mold, excess liquid is not necessarily required for the distribution to be sufficient for formation of the implant. In particular, in certain cases autologous tissue that has been removed from the subject may be especially suitable for forming the implant, and such tissue may exist in a form such as a tissue core or plug reasonably well-suited to being disposed in the mold without the need to add liquid medium. In various embodiments, a biocompatible carrier is added to the mold. The carrier is added to the mold before, during or after adding the biological agent such as tissue particles, cells, collagen, ECM or a tissue-engineered scaffold. In various configurations, a carrier can be added to a mold as a liquid. Such a carrier can embed the one or more tissue particles, and can also form a solid. In various aspects, a liquid carrier can fill space within the mold and therefore can have a shape substantially conforming to the contours of the mold. Because the mold has a shape substantially conforming to the contours of the defect, the carrier can have a shape substantially conforming to contours of the tissue defect. In various aspects, a carrier can be a biological adhesive such as a fibrin glue. As used herein, “fibrin” and “fibrin glue” include fibrin generators such as mixtures of fibrinogen and thrombin (Gibble, J W and Ness, P M, Transfusion 30: 741-747,1990; Alston, S et al., Translational Research 149: 187-195, 2007). In non-limiting example, a fibrin glue can be a commercially available fibrin glue such as Tisseel® VH fibrin sealant (Baxter Healthcare Corporation, Westlake Village, Calif.), which can be prepared for use according to manufacturer's instructions. In other configurations, a biocompatible carrier can comprise at least one biocompatible polymer, such as, without limitation, a fibrinogen, a thrombin, a fibrin, a type I collagen, a type II collagen, a type III collagen, a gelatin, a fibronectin, a laminin, a hyaluronic acid, a hydrogel, a pegylated hydrogel, a chitosan or a combination thereof. In addition, in some aspects, a biocompatible polymer can be autologous to the intended recipient of an implant, and can be, without limitation, an autologous plasma protein such as autologous thrombin, autologous fibrinogen, autologous fibrin and/or autologous fibronectin. In addition or alternatively, in various configurations, a biocompatible carrier can comprise a biocompatible gel, which can be, without limitation, a starch gel, an agarose gel, a polyacrylamide gel or a combination thereof. In various configurations, a biological agent such as tissue particles within a mold can be arranged such that the particles are distributed substantially uniformly within the mold. In various configurations, instruments and tools such as forceps and needles can be used to arrange the particles. In some configurations, the particles and the carrier can together comprise a first layer, within which the particles can be distributed substantially uniformly. In various aspects, the carrier can congeal, thereby forming an implant having contours substantially corresponding to those of the mold and hence to a tissue defect. In various aspects, the distributing can be effected before or after removal of the liquid, or after addition of a biocompatible carrier (see below). In some aspects, combining a biological agent such as tissue particle and a biocompatible carrier such as a fibrin glue can form a composite. Thus, an implant or a first layer thereof can comprise particles which are immobilized and distributed substantially uniformly throughout a biocompatible carrier.
- In various configurations, a second or additional layer can be formed in a mold. Such a layer can be added adjacent to a first layer, for example, by adding a layer of fibrin glue over a previously formed layer comprising fibrin glue and tissue particles. A second or additional layer can comprise components which are the same or different from those of the first layer. In various aspects, a second or additional layer can comprise at least one biocompatible carrier. In various aspects, a second layer can also comprise one or more bioactive agents such as one or more growth factors, one or more bioactive peptides, and/or cell populations. In various aspects, a second layer can comprise a biocompatible gel, and/or tissue particles such as cartilage tissue particles.
- Because an implant will also retain its shape after it is formed, the implant and the mold can be separated in various aspects. Separation can be effected using methods well known to skilled artisans and will depend in part on the material used for the mold. For example, one or more slits can be made in a mold with a scalpel, and pieces of the mold can be pulled away from the implant with the aid of forceps. In some aspects, such as with a mold made of pre-perforated material, the mold may be torn or peeled away from the implant with or without the aid of a surgical instrument. In the case of a mold made of a wax for example, the mold may be melted for removal. In other aspects, certain mold materials such as for example hydrogels may be readily susceptible to being dissolved away using a chemical agent. It is further contemplated that other physical methods and tools such as those involving laser or electrocautery may be sued to remove the mold from the implant.
- In some aspects, an implant can be flexible yet resilient to deformation, so that it can return substantially to its original shape following a deformation, for example after passaging through a hollow needle. Following separation of an implant from a mold, the implant can be applied to the tissue defect. In various aspects of the methods described herein, applying an implant to a tissue defect such as a cartilage defect can comprise inserting the implant at the tissue defect. In some aspects, a method can further include affixing the implant to the tissue defect. In some aspects, affixing an implant can include securing the implant to the tissue defect using methods and materials well known to skilled artisans such as, for example, biocompatible glues, sutures, staples, or pins. In non-limiting example, a biological glue can be used to affix an implant to a tissue defect after the contours of the implant are apposed to the corresponding contours of the defect.
- In some alterative aspects, a mold can comprise a bioabsorbable substrate material such as a polyester. Moreover, it is envisioned that a mold formed at the site of a defect in vivo may also be withdrawn from the defect site, for example through a hollow needle, and upon returning substantially to its original shape following deformation, is then used ex vivo for formation of the implant. The mold and implant are then together introduced to the defect site through the hollow needle and together applied to the defect site. In such cases, a combination of mold and implant can be applied to a tissue defect without separating the mold from the implant. In aspects in which an implant is deformable, an implant can be administered to a subject by injecting the implant into the subject at the site of the tissue defect using a syringe and a hypodermic needle. In aspects in which a combination of a mold and implant is inserted at a tissue defect, the mold can be separated from the implant by standard surgical procedures known to skilled artisans, such as, without limitation, slicing of the mold followed by removal of the mold from the defect.
- In various methods of the present teachings, tissue particles can be initially carried or suspended in a liquid medium. Such a liquid medium is, in various aspects, a cell, tissue or organ storage medium, such as, without limitation, a medium disclosed in U.S. Patent application publication 2005152882 (the disclosure of which is herein incorporated by reference in its entirety), for example Dulbecco's Modified Eagle's Medium (DMEM) or Roswell Park Memorial Institute Medium (RPMI).
- In some configurations, an implant and/or a mold of the present teachings can further comprise at least one bioactive agent, such as, without limitation, a hormone, a growth factor, a pharmaceutical compound, a bioactive peptide, a nucleotide such as an RNAi molecule, a vector, a plurality of cells, and the like. The bioactive agent can be a constituent of any layer of an implant. A growth factor can be, without limitation, a TGF-β, a bone morphogenetic protein, a growth differentiation factor, ADMP-1, a fibroblast growth factor, a hedgehog protein, an insulin-like growth factor, a platelet-derived growth factor, an interleukin, a colony-stimulating factor, an EGF or an activin. A pharmaceutical compound can be, without limitation, an analgesic, an anesthetic such as a local anesthetic, or a cyclooxygenase inhibitor. A bioactive peptide can be, without limitation, neuropeptide Y, secretin, cholecystokinin, or a cell-penetrating peptide such as penetratin, substance P or R9 or for example any bioactive peptide with antimicrobial activity. In some aspects, a bioactive agent can comprise a plurality of cells. Such cells can be, without limitation, chondrocytes, osteoblasts, mesenchymal stem cells, neuronal cells, T cells, B cells, neuronal cells, liver cells, mesenchymal stem cells, adipocytes, renal cells, lung cells and combinations thereof. In some aspects, the cells can be autologous to an intended recipient of an implant, and can be obtained directly from the intended recipient or grown in vitro prior to adding to an implant. In some aspects, the bioactive agent may comprise a nucleotide. A nucleotide can be a naturally occurring sequence of DNA or RNA, synthetic DNA or RNA, or chemically modified DNA or RNA, such as chemically modified otherwise naturally occurring RNAi molecules. In some aspects, the bioactive agent may comprise a vector, for example for introducing a genetic sequence to the implant. A vector can be for example a viral vector.
- In various embodiments of the present teachings, a subject can be a mammal, which can be a human or a non-human mammal. In some configurations, a human subject can be a human in need of treatment of a tissue defect, such as a cartilage defect. In some configurations, a human subject can have a degenerate or damaged cartilage such as a hyaline cartilage comprised by a joint.
- In various aspects of the present teachings, a mold and an implant formed therein can be three dimensional, such as when its shape corresponds to the contours of a tissue defect. Thus, the present teachings provide implants which are not limited to two-dimensional structures, such as films or laminates. In other aspects, a mold and implant formed therein can be substantially cylindrical in shape, such as, without limitation, when a tissue defect such as a cartilage defect is prepared by a surgeon to include a substantially cylindrical aperture. In these configurations, a caregiver such as a surgeon can, prior to forming a mold, prepare a tissue defect such as a cartilage defect for receiving an implant by removing tissue from the defect, such that a circular or cylindrical defect remains. Hence, in some configurations, the methods can include preparing a tissue defect for receiving an implant. The preparation can comprise modifying the defect to comprise a substantially cylindrical aperture. However, it will be noted that an advantage of the present mold, implant and related methods and kits is the ability to adapt the shape of the mold and ultimately the shape of the implant to any shape that helps repair the defect while also preserving the greatest amount of healthy tissue. The site-specific mold and implant can avoid the need to remove healthy tissue to adapt the shape of the defect to a particular predetermined shape of the implant. In addition, the present mold, implant, related methods and kits are well-suited for use in a “tiling” approach using multiple implants at a defect site.
- In some embodiments of the present teachings disclosing implants comprising a mixture of at least one biological agent and a biocompatible carrier, as well as methods for forming such implants, a biological agent can comprise a plurality of tissue particles, such as cartilage particles. In other aspects, a biological agent can comprise a population of cells. A population of cells of these embodiments can comprise, without limitation, a population of chondrocytes, a population of fibroblasts, a population of tendoncytes, a population of bone cells such as osteoblasts, a population of kidney cells, a population of lymphocytes such as T lymphocytes or B lymphocytes, a population of hepatocytes, and/or a population of stem cells such as mesenchymal stem cells or embryonic stem cells, or a combination of any such cell populations. In various configurations, the inserting and the affixing of an implant to a tissue defect can be accomplished using methods well known to skilled artisans, such as inserting the implant using a minimally invasive surgical technique (MIS), such as arthroscopically. An MIS, for example, includes a mini-open arthrotomy with minimal disruption of the surrounding joint structure, typically involving a smaller incision than incisions required in regular open cartilage repair surgeries. In other aspects, the present mold, implant and related methods of forming and using same contemplate their application in situations involving defects to bone tissue underlying all or a portion of the tissue defect, for example the cartilage tissue defect. For example, alternative materials such as engineered bone tissue and/or trabecular metal may be used to reconstruct a bone tissue defect underlying a cartilage tissue defect.
-
FIG. 1 is a flow diagram illustrating the steps in amethod 100 for repairing tissue defects according to the present teachings. By using an in vivo molding approach to determine the shape and dimensions of the implant, the method provides implants that are very well fit to the specific tissue defect. In afirst step 101, a surgeon, technician or other individual trained in orthopedic surgical techniques, applies the substrate material having shape memory, to all or a portion of the tissue defect to be repaired. The tissue defect is, for example, a cartilage tear in a major joint such as the knee. Thus the mold is prepared in vivo in the subject having the tissue defect. The process of applying the substrate material to all or a portion of the tissue defect, for example by manually pressing with or without aid of a surgical instrument, conforms 102 the substrate material to the contours of the tissue defect or portion thereof. - Depending on the substrate material being used, a wait period (not itemized in
FIG. 1 ) may be required in order to allow the substrate material to undergo processes necessary for the material to retain the contours of the tissue defect or portion thereof to which the substrate material has been applied. For example, if the substrate material is a curable plastic or polymerizing plastic, typically a period of time that varies with the type of plastic used should elapse before the material attains properties sufficient to retain the geometry of the tissue defect. Commercially available epoxies and other curable or polymerizing plastics for such purposes are well known and should be used according to manufacturer's instructions for the process of curing or polymerizing. If the substrate material being used is a metal foil, the foil immediately retains the geometry of the tissue defect to which it has been firmly applied. In any case, once the individual preparing the mold ascertains that the substrate material has attained sufficient shape memory of the tissue defect or portion thereof, the individual removes 103 the mold from the tissue defect, typically by simply using gloved fingers or with a sterile surgical instrument. The implant will be formed ex vivo using the mold formed in vivo. - To form the
implant 104, at least a first layer of implant material is placed 105 into the mold. The implant material includes at least a biological agent such as tissue particles. The tissue particles, e.g. cartilage particles, may be further maintained in a liquid medium as described elsewhere herein. The liquid medium can facilitate delivery of the tissue particles into the mold. If a liquid medium is used, it is removed from the mold by aspiration, or by piercing or perforating the mold to drain the liquid after the tissue particles are placed in the mold. In one embodiment, the substrate material is perforated to start with, or is a mesh type material sufficient to initially receive an implant material including a liquid constituent, and then to allow the liquid constituent to drain from the mold after a short period of time during which the implant material is distributed within the mold. In another illustrative embodiment, a biocompatible carrier is also added to the mold to form a first layer of the implant. It should be noted however that the biocompatible carrier may be added to the mold before, during or after placing the tissue particles in the mold. For example, in one aspect fibrin can be combined directly with cartilage tissue particles with or without medium. In alternative embodiments, forming the mold may also include adding a bioactive agent or agents to the mold, thereby forming another layer of the implant, or as part of the first layer. As described elsewhere herein, adding a bioactive agent or agents may include adding growth factors or hormones, pharmaceutical compounds, bioactive peptides, nucleotides, vectors, or other cells. - Referring again to
FIG. 1 , ultimately the implant is separated from themold 106, and the implant is applied 107 to the tissue defect or portion thereof to which the implant now conforms. It should be noted that the implant may be applied to the tissue defect together with the mold first, and the mold then separated from the implant after implantation, or the mold may be removed from the implant before the implant is applied to the tissue defect. In either case, the implant comprising at least the tissue particles and a biocompatible carrier, is made contour-specific for the particular tissue defect and therefore very well fit to the tissue defect. It is believed that the high fit specificity of the implant improves recovery speed and outcomes. - In another aspect, the present teachings encompass a kit for forming the aforementioned mold and implant for repairing a tissue defect. The mold materials and implant materials may be advantageously provided in kit form including separately packaged amounts of each type of material. In a kit the amounts of each material can be for example amounts sufficient for the treatment or repair of a defect of a predetermined size. In one aspect, a kit includes an amount of the pliable substrate for forming the mold as described herein, and the biological agent such as a plurality of cells or tissue particles. In another aspect, the kit may further comprise an amount of the biocompatible carrier. Alternatively, a kit can include an amount of the pliable substrate and an amount of the carrier, with the biological agent such as tissue particles or cells to be provided from another source. In an exemplary embodiment of a kit, each component of the kit is packaged separately in sterile packaging or in packaging susceptible to sterilization. The biological agent such as cells or tissue particles may be in a container such as a glass or plastic vial and may further be carried or suspended in a liquid storage medium suitable for maintaining cells, tissues or organs. In any kits containing cells or tissue particles in liquid storage medium, the kits may further include an absorbent material in the form for example of a pad or wipe for absorbing excess liquid medium from the mold after the biological agent has been introduced to the mold. The pliable substrate can be wrapped or sealed separately in a paper or plastic wrapper, sterilized blister pack or the like. The biocompatible carrier, for example fibrin, can also be contained in a separate glass or plastic vial or other compact container. The kit may optionally further include one or more syringes or other delivery device(s) for introducing the implant material and carrier to the mold. Kits may optionally further include one or more additional containers each storing a bioactive agent such as growth factor or a pharmaceutical agent that may be added to the implant. The kit further includes, for example, printed instructions for forming the mold and the implant and for using the implant to repair a tissue defect. All elements of the kit are provided together in suitable amounts in a box or other suitable packaging.
- The following examples are provided for illustrative purposes only and are not to be construed as limiting of claim scope. The description of an article, a composition, or a method in an example does not imply that the described article or composition has, or has not, been produced, or that that the described method has, or has not, been performed, regardless of verb tense. The methods and compositions described throughout this specification utilize laboratory techniques well known to skilled artisans such as can be found in routinely available laboratory manuals.
- This example illustrates formation of a mold.
- In this example, a sterile piece of aluminum foil having sufficient moldability and rigidity (shape memory) is applied by physician to a cartilage injury. In this case, the physician uses her fingers or a surgical instrument such as a spatula to press the aluminum foil into the cartilage defect so that the foil is in extensive contact with the base and side walls of the defect. This shaping results in a mold which can be used to form an implant which matches the size and shape of the defect (
FIG. 1 ). - This example illustrates formation of an implant of the present teachings using a mold.
- In this example, a syringe is used to transfer cartilage tissue fragments and storage medium to the base of an aluminum foil mold of a cartilage defect, such as the mold illustrated in Example 1. Excess fluid is removed by aspiration, and also by introducing holes in the base of the mold using a scalpel. The mold is contacted with an absorbent sterile pad to absorb liquid through the holes. However, enough fluid remains so that the particulate tissue pieces are not clumped together (
FIG. 2 ). The pieces distribute evenly across the surface of the base of the foil mold. A layer of fibrin is then gently added to embed the cartilage particles within the mold. More fibrin is then overlaid on the first layer to increase the thickness of the implant. The skirt of the foil mold is then gently pulled to straighten the foil, or pulled or peeled away using a surgical instrument such as a forceps This action releases the implant from the foil mold, which is now available for implantation at a cartilage defect. - This example illustrates formation of an implant in an alternative aspect of the present teachings.
- Example 2 above describes formation of a implant using a multiple step process including first the introduction of cartilage tissue fragments to the mold followed by introduction of fibrin to the mold. In this example, an implant is formed in a “single-step” process. Cartilage tissue fragments are combined with fibrin and the combination is introduced to the mold, also using a syringe. A pharmaceutical agent such as a growth factor is optionally added to the combination before introducing the combination the mold. This approach is well-suited for carrier materials that have a well-defined and predictable setting time.
- This example illustrates transfer of an implant to a tissue defect.
- In this example, a cartilage defect in a cadaver is exposed. A fibrin adhesive is applied to the base of the cartilage defect, and the implant of Example 2 is gently lifted with a spatula and placed into the defect such that contours of the defect and the implant correspond (
FIG. 3 ). The implant is then gently pressed against the defect and pulled with forceps so that the implant fits snugly in the defect. Optionally, more fibrin is then added around and over the implant to fill the defect to the extent needed. - This example illustrates transfer of an implant to a tissue defect.
- In this example, a cartilage defect in a cadaver is exposed. A fibrin adhesive is applied directly to the intended contact surface of the implant of Example 2, and the implant of is gently lifted with a spatula and placed into the defect such that contours of the defect and the implant bearing the previously applied layer of fibrin adhesive correspond. The implant is then gently pressed against the defect and pulled with forceps so that the implant fits in the defect. More fibrin is optionally then added around and over the implant to fill the defect as may be needed.
- This example illustrates a protocol for treating a cartilage defect.
- In this example, an autologous fibrin adhesive is prepared at least one week in advance of surgery. Alternatively, a commercially prepared fibrin as obtained off the shelf. A medial or lateral parapatellar mini-arthrotomy is performed using a tourniquet (which need not be inflated). The defect area is marked with a sterile surgical marker. The cartilage tissue is removed within the defect area with a curette, thereby creating a well-defined vertical defect perimeter. The defect base is then cleared to remove the calcified cartilage layer, taking care to avoid violating the subchondral cortical bone plate. If subchondral bone bleeding occurs, it must be stopped before implantation of an implant of the present teachings. The defect and surrounding tissue are irrigated frequently with normal saline during the surgery.
- Sub-chondral bleeding: methods for controlling and stopping subchondral bleeding include: a) use of neuro-patties soaked with a dilute 1:1000 epinephrine and sterile saline solution; b) direct application of thrombin to the site of bleeding; c) electrocautery using a needle-tipped electrocautery device to cauterize only the bleeding points, not the entire base of the defect. Electrocautery can be used, particularly if bleeding is especially difficult to control, for example in a patient who had previous marrow stimulation.
- Defect sizing: with the aid of a sterile flat-ended rod, a sterile thin foil is pressed into the defect so that the outer shape of the foil fits snugly into the defect base and vertical wall. The approximate surface area of the defect is measured to determine the approximate amount of cartilage particles needed. If DeNovo® NT particles (Isto Technologies, Inc., St. Louis, Mo. and Zimmer, Inc., Warsaw, Ind.) are used, one pack of particles is needed for each about 0.5 to about 3.0 cm2 defect or for an average of about 2.5 cm2 defect. The foil mold is removed from the defect and placed on sterile gauze or a sterile absorbent plant. The defect may be documented photographically, including a ruler showing two dimensions at 90 degrees to each other.
- Implant Preparation: A clear sterile piece of plastic tubing, at least 30 mm in length, is attached to a sterile syringe with a luer tip orifice of <1 mm. The lid of a package of DeNovo® NT particles is opened, and the cartilage tissue particles and medium are aspirated using the syringe. The cartilage particles will be contained within the tubing, while the storage medium will be aspirated into the syringe barrel. The cartilage and the storage medium are transferred to the foil old. Excess storage medium is aspirated by aspiration until only a shallow pool of the medium remains. This is done so that the cartilage pieces are not clumped together. The tissue pieces are then distributed evenly across the surface base of the foil mold with the tip of the syringe. Remaining liquid is removed by aspiration while avoiding further movement of the cartilage pieces. A sharp tip tool such as a scalpel is also used to make small perforations in the foil at various locations to allow excess liquid to be absorbed by an absorbent sterile gauze or pad underlying the foil mold. A layer of fibrin glue is then gently applied to embed the particulate tissue pieces. More fibrin is then applied, such that the tissue/fibrin composite fills to about ¾ the depth of the mold. The fibrin is then set for 5-10 minutes in accordance with fibrin preparation instructions. The edges of the foil mold are then gently pulled to straighten the foil so that the tissue/fibrin implant separates from the vertical walls of the foil mold. The implant can then be lifted from the mold base using a sterile flat instrument such as a spatula. The implant is now ready for implantation.
- Alternatively, the implant is prepared using the single-step process in which the fibrin is added directly to the cartilage particles in the syringe tubing by aspirating the fibrin after any excess storage medium is aspirated. The fibrin may otherwise be added directly to the cartilage particles and medium in the tubing and syringe in the case where no excess storage medium is aspirated. In either case, the cartilage tissue particles together with the fibrin may be gently agitated using the action of the syringe plunger within the syringe barrel to promote gentle mixing of the fibrin with the cells and any remaining medium. The mixture of cartilage particles, fibrin and any remaining medium is then introduced across the surface base of the foil mold with the tip of the syringe. Remaining steps for removal and use of the implant thus formed are as described above.
- Fixation of an implant into a cartilage defect: Initially, the defect area and the implant are gently dried using sterile surgical gauze. A very thin layer of fibrin glue, approx. 0.01-0.1 ml to cover then entire base of the defect. The implant is then placed on the defect, ensuring a matched fit between the contours of the defect and those of the implant. The implant is then gently held in close contact with the base and edges of the defects (e.g., using a finger). The implant should be recessed by approximately 0.5 mm relative to surrounding native cartilage. The implant is held against the defect and gently stretched (using instruments such as a pair of surgical forceps) so that the implant fits snugly to the defect wall. The fibrin is allowed to cure for at least 5 minutes, and care must be taken not to manipulate or dislodge the implant during the curing. The transfer of the implant to the defect can be documented photographically.
- Wound closure: Based upon the physician's judgment and standard of care, drains can be inserted within the wound site. The joint capsule, fascial layers and skin can be closed using standard suture and surgical techniques.
- It is to be understood that the specific embodiments of the present teachings as set forth herein are not intended as being exhaustive or limiting, and that many alternatives, modifications, and variations will be apparent to those of ordinary skill in the art in light of the foregoing examples and detailed description. Accordingly, the present teachings are intended to embrace all such alternatives, modifications, and variations that fall within the spirit and scope of the following claims.
- All publications, patents, patent applications and other references cited in this application are herein incorporated by reference in their entirety as if each individual publication, patent, patent application or other reference were specifically and individually indicated to be incorporated by reference.
Claims (76)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/101,553 US20090012629A1 (en) | 2007-04-12 | 2008-04-11 | Compositions and methods for tissue repair |
US13/327,265 US9138318B2 (en) | 2007-04-12 | 2011-12-15 | Apparatus for forming an implant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91142907P | 2007-04-12 | 2007-04-12 | |
US12/101,553 US20090012629A1 (en) | 2007-04-12 | 2008-04-11 | Compositions and methods for tissue repair |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/327,265 Continuation US9138318B2 (en) | 2007-04-12 | 2011-12-15 | Apparatus for forming an implant |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090012629A1 true US20090012629A1 (en) | 2009-01-08 |
Family
ID=39864337
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/101,553 Abandoned US20090012629A1 (en) | 2007-04-12 | 2008-04-11 | Compositions and methods for tissue repair |
US13/327,265 Active US9138318B2 (en) | 2007-04-12 | 2011-12-15 | Apparatus for forming an implant |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/327,265 Active US9138318B2 (en) | 2007-04-12 | 2011-12-15 | Apparatus for forming an implant |
Country Status (5)
Country | Link |
---|---|
US (2) | US20090012629A1 (en) |
EP (1) | EP2134297B1 (en) |
AU (1) | AU2008240191B2 (en) |
CA (1) | CA2684040C (en) |
WO (1) | WO2008128075A1 (en) |
Cited By (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120116523A1 (en) * | 2009-07-10 | 2012-05-10 | Milux Holding Sa | Joint device and method |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US8497121B2 (en) | 2006-12-20 | 2013-07-30 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US8518433B2 (en) | 2003-12-11 | 2013-08-27 | Zimmer, Inc. | Method of treating an osteochondral defect |
US20140012393A1 (en) * | 2011-03-31 | 2014-01-09 | Inje University Industry-Academic Cooperation Foundation | Complex support body for regenerating bone-cartilage, method for manufacturing thereof, and composition for treating bone and cartilage related diseases comprising same as active ingredient |
WO2014028327A1 (en) * | 2012-08-15 | 2014-02-20 | Mimedx Group Inc. | Micronized placental tissue compositions and methods of making and using the same |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8906110B2 (en) | 2007-01-24 | 2014-12-09 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US9133438B2 (en) | 2011-06-29 | 2015-09-15 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
US9463206B2 (en) | 2011-12-22 | 2016-10-11 | Mimedx Group, Inc. | Cross-linked dehydrated placental tissue grafts and methods for making and using the same |
US9655948B1 (en) | 2013-01-17 | 2017-05-23 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9662355B2 (en) | 2013-01-18 | 2017-05-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US9827293B2 (en) | 2013-01-17 | 2017-11-28 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
US10052351B2 (en) | 2014-01-17 | 2018-08-21 | Mimedx Group, Inc. | Method for inducing angiogenesis |
US10092600B2 (en) | 2013-07-30 | 2018-10-09 | Musculoskeletal Transplant Foundation | Method of preparing an adipose tissue derived matrix |
US10105397B2 (en) | 2011-02-14 | 2018-10-23 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10159744B2 (en) | 2012-11-19 | 2018-12-25 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
US10167449B2 (en) | 2013-04-19 | 2019-01-01 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
US10206977B1 (en) | 2013-01-18 | 2019-02-19 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
US10232085B2 (en) | 2011-02-14 | 2019-03-19 | Mimedx Group, Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
US10441664B2 (en) | 2012-11-19 | 2019-10-15 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US10517931B2 (en) | 2013-01-17 | 2019-12-31 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10617785B2 (en) | 2014-08-28 | 2020-04-14 | Mimedx Group, Inc. | Collagen reinforced tissue grafts |
US10857266B2 (en) | 2012-08-15 | 2020-12-08 | Mimedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
CN113198047A (en) * | 2021-05-14 | 2021-08-03 | 西安市红会医院 | Preparation method of cartilage regeneration support material for orthopedic sports trauma |
US11338063B2 (en) | 2012-08-15 | 2022-05-24 | Mimedx Group, Inc. | Placental tissue grafts modified with a cross-linking agent and methods of making and using the same |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8911474B2 (en) | 2009-07-16 | 2014-12-16 | Howmedica Osteonics Corp. | Suture anchor implantation instrumentation system |
CA2713309C (en) | 2009-08-20 | 2013-07-02 | Howmedica Osteonics Corp. | Flexible acl instrumentation, kit and method |
US9795398B2 (en) | 2011-04-13 | 2017-10-24 | Howmedica Osteonics Corp. | Flexible ACL instrumentation, kit and method |
US9445803B2 (en) | 2011-11-23 | 2016-09-20 | Howmedica Osteonics Corp. | Filamentary suture anchor |
US8821494B2 (en) | 2012-08-03 | 2014-09-02 | Howmedica Osteonics Corp. | Surgical instruments and methods of use |
US9186380B2 (en) | 2012-11-15 | 2015-11-17 | Allosource | Minced cartilage systems and methods |
US9078740B2 (en) | 2013-01-21 | 2015-07-14 | Howmedica Osteonics Corp. | Instrumentation and method for positioning and securing a graft |
AU2014218734B2 (en) | 2013-02-22 | 2018-03-15 | Allosource | Cartilage mosaic compositions and methods |
US9402620B2 (en) | 2013-03-04 | 2016-08-02 | Howmedica Osteonics Corp. | Knotless filamentary fixation devices, assemblies and systems and methods of assembly and use |
US9788826B2 (en) | 2013-03-11 | 2017-10-17 | Howmedica Osteonics Corp. | Filamentary fixation device and assembly and method of assembly, manufacture and use |
US9463013B2 (en) | 2013-03-13 | 2016-10-11 | Stryker Corporation | Adjustable continuous filament structure and method of manufacture and use |
WO2014151939A1 (en) | 2013-03-15 | 2014-09-25 | Allosource | Perforated osteochondral allograft compositions |
US10292694B2 (en) | 2013-04-22 | 2019-05-21 | Pivot Medical, Inc. | Method and apparatus for attaching tissue to bone |
US10610211B2 (en) | 2013-12-12 | 2020-04-07 | Howmedica Osteonics Corp. | Filament engagement system and methods of use |
US9986992B2 (en) | 2014-10-28 | 2018-06-05 | Stryker Corporation | Suture anchor and associated methods of use |
US10568616B2 (en) | 2014-12-17 | 2020-02-25 | Howmedica Osteonics Corp. | Instruments and methods of soft tissue fixation |
USD902405S1 (en) | 2018-02-22 | 2020-11-17 | Stryker Corporation | Self-punching bone anchor inserter |
Citations (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3302289A (en) * | 1963-10-21 | 1967-02-07 | Lawrence A Spaulding | Impression and bite tray for dentistry |
US4566138A (en) * | 1983-03-08 | 1986-01-28 | Zimmer, Inc. | Prosthetic device with spacers |
US4640834A (en) * | 1984-03-09 | 1987-02-03 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of inactivating reproducible filterable pathogens in blood products as well as a method of producing blood products |
US4641651A (en) * | 1983-09-22 | 1987-02-10 | Card George W | Cartilage punch and modified prosthesis in tympanoplasty |
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
US4818633A (en) * | 1985-11-14 | 1989-04-04 | Imperial Chemical Industries Plc | Fibre-reinforced metal matrix composites |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US4911720A (en) * | 1983-03-10 | 1990-03-27 | Collier John P | Particular surface replacement prosthesis |
US4997445A (en) * | 1989-12-08 | 1991-03-05 | Zimmer, Inc. | Metal-backed prosthetic implant with enhanced bonding of polyethylene portion to metal base |
US4997444A (en) * | 1989-12-28 | 1991-03-05 | Zimmer, Inc. | Implant having varying modulus of elasticity |
US5002071A (en) * | 1987-04-03 | 1991-03-26 | Research Development Foundation | Injectable soft tissue augmentation materials from the placenta and their method of manufacture |
US5002582A (en) * | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
US5080674A (en) * | 1988-09-08 | 1992-01-14 | Zimmer, Inc. | Attachment mechanism for securing an additional portion to an implant |
US5092887A (en) * | 1991-08-12 | 1992-03-03 | El Gendler | Artificial ligament produced from demineralized bone for the replacement and augmentation of ligaments, tendons and other fibrous connective tissue |
US5189148A (en) * | 1989-07-07 | 1993-02-23 | Takeda Chemical Industries, Inc. | Stabilized fgf composition and production thereof |
US5198308A (en) * | 1990-12-21 | 1993-03-30 | Zimmer, Inc. | Titanium porous surface bonded to a cobalt-based alloy substrate in an orthopaedic implant device |
US5281422A (en) * | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
US5282861A (en) * | 1992-03-11 | 1994-02-01 | Ultramet | Open cell tantalum structures for cancellous bone implants and cell and tissue receptors |
US5290558A (en) * | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
US5387243A (en) * | 1992-11-23 | 1995-02-07 | Zimmer, Inc. | Method for converting a cementable implant to a press fit implant |
US5482929A (en) * | 1991-12-26 | 1996-01-09 | Kaken Pharmaceutical Co., Ltd. | Composition of stabilized fibroblast growth factor |
US5496375A (en) * | 1994-09-14 | 1996-03-05 | Zimmer, Inc. | Prosthetic implant with circumferential porous pad having interlocking tabs |
US5605887A (en) * | 1993-03-01 | 1997-02-25 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
US5612028A (en) * | 1988-02-17 | 1997-03-18 | Genethics Limited | Method of regenerating or replacing cartilage tissue using amniotic cells |
US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5714371A (en) * | 1995-05-12 | 1998-02-03 | Schering Corporation | Method for refolding insoluble aggregates of hepatitis C virus protease |
US5713374A (en) * | 1995-02-10 | 1998-02-03 | The Hospital For Joint Diseases Orthopaedic Institute | Fixation method for the attachment of wound repair materials to cartilage defects |
US5723010A (en) * | 1995-03-31 | 1998-03-03 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US5723011A (en) * | 1992-12-21 | 1998-03-03 | Zimmer, Inc. | Prosthetic implant and method of making same |
US5734959A (en) * | 1995-10-12 | 1998-03-31 | Zimmer, Inc. | Method of making an orthopaedic implant having a porous surface using an organic binder |
US5864016A (en) * | 1991-06-20 | 1999-01-26 | Immuno Aktiengesellschaft | Blood product, a method of producing the same and a method of determining the virus inactivation capacity of an inactivation treatment |
US5866630A (en) * | 1993-12-06 | 1999-02-02 | Minnesota Mining And Manufacturing Company | Optionally crosslinkable coatings compositions and methods of use |
US5866415A (en) * | 1997-03-25 | 1999-02-02 | Villeneuve; Peter E. | Materials for healing cartilage and bone defects |
US6022361A (en) * | 1998-10-09 | 2000-02-08 | Biointerventional Corporation | Device for introducing and polymerizing polymeric biomaterials in the human body and method |
US6025334A (en) * | 1994-04-28 | 2000-02-15 | Les Laboratoires Aeterna Inc. | Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof |
US6171610B1 (en) * | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
US6174313B1 (en) * | 1990-06-28 | 2001-01-16 | Peter M. Bonutti | Apparatus and method for tissue removal |
US6183737B1 (en) * | 1997-10-30 | 2001-02-06 | The General Hospital Corporation | Bonding of cartilage pieces using isolated chondrocytes and a biological gel |
US6187329B1 (en) * | 1997-12-23 | 2001-02-13 | Board Of Regents Of The University Of Texas System | Variable permeability bone implants, methods for their preparation and use |
US6336930B1 (en) * | 2000-03-07 | 2002-01-08 | Zimmer, Inc. | Polymer filled bone plate |
US20020004038A1 (en) * | 1996-04-30 | 2002-01-10 | Baugh Robert F. | Autologous platelet gel spray delivery system |
US6338878B1 (en) * | 1999-04-28 | 2002-01-15 | Alcatel | Method to improve degree of cure for ultraviolet curable optical fiber coating by actively removing heat from the coating during irradiation |
US20020009805A1 (en) * | 1999-07-06 | 2002-01-24 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Scaffold matrix and tissue maintaining systems |
US20020012705A1 (en) * | 1998-04-08 | 2002-01-31 | Chondros, Inc. | Polymer constructs |
US20020183850A1 (en) * | 2000-08-28 | 2002-12-05 | Felt Jeffrey C. | Method and system for mammalian joint resurfacing |
US6503277B2 (en) * | 1991-08-12 | 2003-01-07 | Peter M. Bonutti | Method of transplanting human body tissue |
US6503267B2 (en) * | 1990-06-28 | 2003-01-07 | Peter M. Bonutti | Surgical devices assembled using heat bondable materials |
US6504079B2 (en) * | 1995-06-07 | 2003-01-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
US20030009235A1 (en) * | 2000-07-19 | 2003-01-09 | Albert Manrique | Osteoimplant and method of making same |
US6513455B2 (en) * | 1999-08-23 | 2003-02-04 | Lafeber, Iii Theodore J. | Pet cage scenery and toys made of molded paper pulp |
US20030040113A1 (en) * | 2001-03-23 | 2003-02-27 | Histogenics Corporation | Composition and methods for the production of biological tissues and tissue constructs |
US20030039695A1 (en) * | 2001-08-10 | 2003-02-27 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Collagen carrier of therapeutic genetic material, and method |
US6676971B2 (en) * | 2000-03-13 | 2004-01-13 | Biocure, Inc. | Embolic compositions |
US20040007890A1 (en) * | 2002-06-26 | 2004-01-15 | Rbw Industries, Inc. | Room expansion system |
US6685987B2 (en) * | 1999-03-12 | 2004-02-03 | Zimmer Technology, Inc. | Enhanced fatigue strength orthopaedic implant with porous coating and method of making same |
US20040030404A1 (en) * | 2000-05-31 | 2004-02-12 | Michaela Noll | Method for cultivating a cartilage replacement and a biomatrix produced according to this method |
US20040030406A1 (en) * | 2000-12-06 | 2004-02-12 | Mitsuo Ochi | Tissue equivalent for transplantation and process for producing the same |
US20040033212A1 (en) * | 2000-07-29 | 2004-02-19 | Thomson Brian Mark | Tissue implant |
US6697143B2 (en) * | 2001-02-12 | 2004-02-24 | Viztec, Inc. | Electrooptical displays constructed with polymerization initiating and enhancing elements positioned between substrates |
US20040127987A1 (en) * | 2002-06-13 | 2004-07-01 | Evans Douglas G. | Devices and methods for treating defects in the tissue of a living being |
US6840960B2 (en) * | 2002-09-27 | 2005-01-11 | Stephen K. Bubb | Porous implant system and treatment method |
US20050026133A1 (en) * | 2002-01-31 | 2005-02-03 | Asahi Techno Glass Corporation | Cryopreservation medium for primate embryo stem cells and cryopreservation method |
US6852330B2 (en) * | 2000-12-21 | 2005-02-08 | Depuy Mitek, Inc. | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US20050032015A1 (en) * | 2003-08-07 | 2005-02-10 | Mcsurdy David W. | System and method for palatal expansion |
US20050038520A1 (en) * | 2003-08-11 | 2005-02-17 | Francois Binette | Method and apparatus for resurfacing an articular surface |
US20050043805A1 (en) * | 2003-08-11 | 2005-02-24 | Chudik Steven C. | Devices and methods used for shoulder replacement |
US20050043814A1 (en) * | 2003-08-20 | 2005-02-24 | Akihiko Kusanagi | Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof |
US20050152882A1 (en) * | 2003-12-11 | 2005-07-14 | Isto Technologies | Particulate cartilage system |
US20060008530A1 (en) * | 2004-07-12 | 2006-01-12 | Isto Technologies, Inc. | Tissue matrix system |
US20060009779A1 (en) * | 2004-06-29 | 2006-01-12 | Keith Collins | Devices for injecting a curable biomaterial into a intervertebral space |
US20060019389A1 (en) * | 2004-07-22 | 2006-01-26 | Avner Yayon | Porous plasma protein matrices and methods for preparation thereof |
US6991652B2 (en) * | 2000-06-13 | 2006-01-31 | Burg Karen J L | Tissue engineering composite |
US6990982B1 (en) * | 1990-06-28 | 2006-01-31 | Bonutti Ip, Llc | Method for harvesting and processing cells from tissue fragments |
US20060024826A1 (en) * | 2001-02-23 | 2006-02-02 | University Of Massachusetts, A Massachusetts Corporation | Tympanic membrane patch |
US20060024373A1 (en) * | 2000-11-14 | 2006-02-02 | N.V.R. Labs Ltd. | Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
US20060029679A1 (en) * | 2001-04-09 | 2006-02-09 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
US20060041270A1 (en) * | 2004-05-07 | 2006-02-23 | Jay Lenker | Medical access sheath |
US20070014867A1 (en) * | 2003-08-20 | 2007-01-18 | Histogenics Corp | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof |
US20070031471A1 (en) * | 2004-06-23 | 2007-02-08 | Minu, L.L.C. | Uses of Amniotic Membranes as Biocompatible Devices |
US20070038299A1 (en) * | 2005-08-12 | 2007-02-15 | Arthrotek, Inc | Multilayer microperforated implant |
US20070041952A1 (en) * | 2005-04-18 | 2007-02-22 | Duke University | Three-dimensional fiber scaffolds for tissue engineering |
US7316822B2 (en) * | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US20080009942A1 (en) * | 2002-03-22 | 2008-01-10 | Histogenics Corp. | Method for in situ repair of injured, damaged, diseased or aged articular cartilage |
US20080031934A1 (en) * | 2006-08-04 | 2008-02-07 | Macphee Martin | Processes for the production of solid dressings for treating wounded tissue |
US20080039940A1 (en) * | 2004-03-11 | 2008-02-14 | Kouji Hashimoto | Biological Tissue Sheet, Method Of Forming The Same And Transplantation Method By Using The Sheet |
US20080039954A1 (en) * | 2006-08-08 | 2008-02-14 | Howmedica Osteonics Corp. | Expandable cartilage implant |
US20080051624A1 (en) * | 2002-06-07 | 2008-02-28 | Bonutti Peter M | Scaffold and method for implanting cells |
US7488348B2 (en) * | 2003-05-16 | 2009-02-10 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US20100015202A1 (en) * | 2007-03-06 | 2010-01-21 | Semler Eric J | Cancellous construct with support ring for repair of osteochondral defects |
US20110009963A1 (en) * | 2002-10-18 | 2011-01-13 | Depuy Mitek, Inc. | Biocompatible scaffold for ligament or tendon repair |
US7879604B2 (en) * | 2004-02-20 | 2011-02-01 | Isto Technoliges, Inc. | Intervertebral disk repair, methods and devices therefor |
Family Cites Families (410)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1347622A (en) | 1919-03-29 | 1920-07-27 | Arthur E Deininger | Vaccine-injector |
US2533004A (en) | 1943-10-27 | 1950-12-05 | John D Ferry | Fibrin clots and methods for preparing the same |
US2621145A (en) | 1949-08-17 | 1952-12-09 | Machteld E Sano | Bone mat compositions |
US3400199A (en) | 1965-02-26 | 1968-09-03 | Leslie L. Balassa | Wound-healing cartilage powder |
USRE28093E (en) | 1962-02-28 | 1974-07-30 | Wound-healing cartilage powder | |
US3478146A (en) | 1965-02-26 | 1969-11-11 | Leslie L Balassa | Wound-healing cartilage powder extracting process |
US3476855A (en) | 1965-02-26 | 1969-11-04 | Leslie L Balassa | Sterilizing and enhancing activity of a finely divided cartilage powder |
US3474146A (en) | 1967-01-03 | 1969-10-21 | Stauffer Chemical Co | Fluorine-containing ethyl disulfides |
US3772432A (en) | 1971-01-11 | 1973-11-13 | Lescarden Ltd | Cartilage compositions for dental use |
US3966908A (en) | 1973-11-29 | 1976-06-29 | Lescarden Ltd. | Method of treating degenerative joint afflictions |
GB2023314B (en) | 1978-06-15 | 1982-10-06 | Ibm | Digital data processing systems |
US4350682A (en) | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
US4440680A (en) | 1980-09-24 | 1984-04-03 | Seton Company | Macromolecular biologically active collagen articles |
DE3105624A1 (en) | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
US4466435A (en) | 1981-09-04 | 1984-08-21 | Murray William M | Bone cement nozzle and method |
US4479271A (en) | 1981-10-26 | 1984-10-30 | Zimmer, Inc. | Prosthetic device adapted to promote bone/tissue ingrowth |
US5656587A (en) | 1982-09-24 | 1997-08-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Promotion of cell proliferation by use of transforming growth factor beta (TGF-β) |
DE3247387C2 (en) | 1982-12-22 | 1984-11-22 | Rolf Prof. Dr.med. 7400 Tübingen Hettich | Method for producing a transplant and device for carrying out the method |
US4522096A (en) | 1983-06-16 | 1985-06-11 | R. J. Reynolds Tobacco Company | Dicing apparatus for sheet material |
GB8318483D0 (en) | 1983-07-08 | 1983-08-10 | Zimmer Deloro Surgical Ltd | Skeletal implants |
EP0133934A3 (en) | 1983-07-29 | 1985-09-18 | NIKEPHARMA S.r.l. | Pharmacologically active 1,3,4-thiadiazol-(3,2-a)-thieno-(2,3-d)-pyrimidin-5-(h)one derivatives |
JPS60109781A (en) | 1983-08-09 | 1985-06-15 | Honda Motor Co Ltd | Synchronous operation controller |
JPS59135054A (en) | 1983-10-03 | 1984-08-03 | 朝倉 由純 | Hip joint |
US4609551A (en) | 1984-03-20 | 1986-09-02 | Arnold Caplan | Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites |
GB8413319D0 (en) | 1984-05-24 | 1984-06-27 | Oliver Roy Frederick | Biological material |
US4863475A (en) | 1984-08-31 | 1989-09-05 | Zimmer, Inc. | Implant and method for production thereof |
US4928603A (en) | 1984-09-07 | 1990-05-29 | The Trustees Of Columbia University In The City Of New York | Method of preparing a cryoprecipitated suspension and use thereof |
US4627879A (en) | 1984-09-07 | 1986-12-09 | The Trustees Of Columbia University In The City Of New York | Fibrin adhesive prepared as a concentrate from single donor fresh frozen plasma |
US4678470A (en) | 1985-05-29 | 1987-07-07 | American Hospital Supply Corporation | Bone-grafting material |
US4660755A (en) | 1985-09-09 | 1987-04-28 | Zimmer, Inc. | Method for constructing a surgical implant |
US4656137A (en) | 1985-09-12 | 1987-04-07 | Lescarden Inc | Method of processing animal cartilage |
US5902741A (en) | 1986-04-18 | 1999-05-11 | Advanced Tissue Sciences, Inc. | Three-dimensional cartilage cultures |
US4963489A (en) | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5032508A (en) | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4714457A (en) | 1986-09-15 | 1987-12-22 | Robert Alterbaum | Method and apparatus for use in preparation of fibrinogen from a patient's blood |
US5254471A (en) | 1986-10-06 | 1993-10-19 | Toray Industries, Inc. | Carrier for cell culture |
US5041138A (en) * | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
US4846835A (en) | 1987-06-15 | 1989-07-11 | Grande Daniel A | Technique for healing lesions in cartilage |
US4952403A (en) | 1987-06-19 | 1990-08-28 | President And Fellows Of Harvard College | Implants for the promotion of healing of meniscal tissue |
US5681353A (en) | 1987-07-20 | 1997-10-28 | Regen Biologics, Inc. | Meniscal augmentation device |
US5306311A (en) | 1987-07-20 | 1994-04-26 | Regen Corporation | Prosthetic articular cartilage |
US5013324A (en) | 1987-08-24 | 1991-05-07 | Zimmer, Inc. | Prosthetic implant with wrapped porous surface |
US5018285A (en) | 1987-08-24 | 1991-05-28 | Zimmer, Inc. | Method of constructing prosthetic implant with wrapped porous surface |
US4851354A (en) | 1987-12-07 | 1989-07-25 | Trustees Of The University Of Pennsylvania | Apparatus for mechanically stimulating cells |
US5139527A (en) | 1987-12-17 | 1992-08-18 | Immuno Aktiengesellschaft | Biologic absorbable implant material for filling and closing soft tissue cavities and method of its preparation |
US5219363A (en) | 1988-03-22 | 1993-06-15 | Zimmer, Inc. | Bone implant |
US5053050A (en) | 1988-04-29 | 1991-10-01 | Samuel Itay | Compositions for repair of cartilage and bone |
US5290552A (en) | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
ATE111360T1 (en) | 1988-05-02 | 1994-09-15 | Project Hear | SURGICAL ADHESIVE MATERIAL. |
US4950483A (en) | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5565519A (en) | 1988-11-21 | 1996-10-15 | Collagen Corporation | Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications |
US5475052A (en) | 1988-11-21 | 1995-12-12 | Collagen Corporation | Collagen-synthetic polymer matrices prepared using a multiple step reaction |
EP0388576B1 (en) | 1989-03-23 | 1993-09-15 | Institut Straumann Ag | Metallic implant |
US5130418A (en) | 1989-05-02 | 1992-07-14 | California Biotechnology Inc. | Method to stabilize basic fibroblast growth factor |
US5226877A (en) | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
DE69004098T2 (en) | 1989-08-10 | 1994-08-04 | Gore & Ass | MEDICAL DISPENSING SYSTEM FOR TISSUE ADHESIVE COMPONENTS. |
GB8927546D0 (en) | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5067964A (en) | 1989-12-13 | 1991-11-26 | Stryker Corporation | Articular surface repair |
US5030215A (en) | 1990-01-03 | 1991-07-09 | Cryolife, Inc. | Preparation of fibrinogen/factor XIII precipitate |
US5514153A (en) | 1990-03-02 | 1996-05-07 | General Surgical Innovations, Inc. | Method of dissecting tissue layers |
US5345927A (en) | 1990-03-02 | 1994-09-13 | Bonutti Peter M | Arthroscopic retractors |
US5217954A (en) | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
US5593425A (en) | 1990-06-28 | 1997-01-14 | Peter M. Bonutti | Surgical devices assembled using heat bonable materials |
US5069881A (en) | 1990-07-10 | 1991-12-03 | Mobay Corporation | Device and method for applying adhesives |
US5067963A (en) | 1990-08-21 | 1991-11-26 | Washington University | Method of making live autogenous skeletal replacement parts |
US5948384A (en) | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
CA2041430C (en) | 1990-10-30 | 2002-11-26 | Jack Eldon Parr | Orthopaedic implant device |
US5226914A (en) | 1990-11-16 | 1993-07-13 | Caplan Arnold I | Method for treating connective tissue disorders |
US5811094A (en) | 1990-11-16 | 1998-09-22 | Osiris Therapeutics, Inc. | Connective tissue regeneration using human mesenchymal stem cell preparations |
DK0564502T3 (en) | 1990-11-27 | 2002-05-13 | Univ Loyola Chicago | Tissue sealant and growth factor-containing preparations that promote accelerated wound healing |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
AU651421B2 (en) | 1990-11-30 | 1994-07-21 | Celtrix Pharmaceuticals, Inc. | Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair |
CA2055966C (en) | 1990-12-19 | 1995-08-01 | Oresta Natalia Fedun | Cell culture insert |
US5206023A (en) | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
US5853746A (en) | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
US5356629A (en) | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US6773458B1 (en) | 1991-07-24 | 2004-08-10 | Baxter International Inc. | Angiogenic tissue implant systems and methods |
US5329846A (en) | 1991-08-12 | 1994-07-19 | Bonutti Peter M | Tissue press and system |
US5270300A (en) | 1991-09-06 | 1993-12-14 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone |
US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
JP3524919B2 (en) | 1991-10-30 | 2004-05-10 | マサチューセッツ インスティテュート オブ テクノロジー | Prevascularized polymeric graft for organ transplantation |
US6818008B1 (en) | 1992-01-07 | 2004-11-16 | Cch Associates, Inc. | Percutaneous puncture sealing method |
US5314476A (en) | 1992-02-04 | 1994-05-24 | Osteotech, Inc. | Demineralized bone particles and flowable osteogenic composition containing same |
US5876452A (en) | 1992-02-14 | 1999-03-02 | Board Of Regents, University Of Texas System | Biodegradable implant |
US5236457A (en) | 1992-02-27 | 1993-08-17 | Zimmer, Inc. | Method of making an implant having a metallic porous surface |
US5326357A (en) | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
DK83092D0 (en) | 1992-06-24 | 1992-06-24 | Unes As | PROCEDURE FOR THE EXTRACTION OF THROMBIN |
US5312417A (en) | 1992-07-29 | 1994-05-17 | Wilk Peter J | Laparoscopic cannula assembly and associated method |
CN1091315A (en) | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | Fibrin sealant compositions and using method thereof |
US5275826A (en) | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
US5443454A (en) | 1992-12-09 | 1995-08-22 | Terumo Kabushiki Kaisha | Catheter for embolectomy |
US5749968A (en) | 1993-03-01 | 1998-05-12 | Focal, Inc. | Device for priming for improved adherence of gels to substrates |
DE4306661C2 (en) | 1993-03-03 | 1995-04-20 | Michael Dipl Biol Sittinger | Process for producing an implant from cell cultures |
US5443510A (en) | 1993-04-06 | 1995-08-22 | Zimmer, Inc. | Porous coated implant and method of making same |
EP2025353A2 (en) | 1993-04-30 | 2009-02-18 | Massachusetts Institute of Technology | Injectable polysaccharide-cell compositions |
US5549904A (en) | 1993-06-03 | 1996-08-27 | Orthogene, Inc. | Biological adhesive composition and method of promoting adhesion between tissue surfaces |
US5795780A (en) | 1993-06-23 | 1998-08-18 | Bristol-Myers Squibb Company | Method of use of autologous thrombin blood fraction in a cell culture with keratinocytes |
US5405742A (en) | 1993-07-16 | 1995-04-11 | Cyromedical Sciences, Inc. | Solutions for tissue preservation and bloodless surgery and methods using same |
EP0641007A3 (en) | 1993-08-31 | 1995-06-21 | Samsung Display Devices Co Ltd | Direct-heating-type dispenser cathode structure. |
US5890898A (en) | 1993-11-08 | 1999-04-06 | Wada; Eric Minoru | Infection control guard for dental air-water syringes |
DE4338129A1 (en) | 1993-11-08 | 1995-05-11 | Zimmer Ag | Process for polymer melt filtration |
US6312668B2 (en) | 1993-12-06 | 2001-11-06 | 3M Innovative Properties Company | Optionally crosslinkable coatings, compositions and methods of use |
IL112580A0 (en) | 1994-02-24 | 1995-05-26 | Res Dev Foundation | Amniotic membrane graft of wrap to prevent adhesions or bleeding of internal organs |
DK0871414T3 (en) | 1994-03-14 | 2004-08-30 | Cryolife Inc | Methods for preparing tissue for implantation |
US5461953A (en) | 1994-03-25 | 1995-10-31 | Mccormick; James B. | Multi-dimension microtome sectioning device |
US5504300A (en) | 1994-04-18 | 1996-04-02 | Zimmer, Inc. | Orthopaedic implant and method of making same |
US5618925A (en) | 1994-04-28 | 1997-04-08 | Les Laboratories Aeterna Inc. | Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof |
US5888220A (en) | 1994-05-06 | 1999-03-30 | Advanced Bio Surfaces, Inc. | Articulating joint repair |
WO1998020939A2 (en) | 1996-11-15 | 1998-05-22 | Advanced Bio Surfaces, Inc. | Biomaterial system for in situ tissue repair |
US5556429A (en) | 1994-05-06 | 1996-09-17 | Advanced Bio Surfaces, Inc. | Joint resurfacing system |
US6140452A (en) | 1994-05-06 | 2000-10-31 | Advanced Bio Surfaces, Inc. | Biomaterial for in situ tissue repair |
US5906827A (en) | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
CA2189646C (en) | 1994-06-24 | 1999-05-25 | Francis E. Dwulet | A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum |
EP0804153B1 (en) | 1994-07-21 | 2003-10-01 | Sirus Pharmaceuticals Ltd. | Composition comprising a tissue glue and an immobilised therapeutic particle |
AU3145795A (en) | 1994-07-26 | 1996-02-22 | Children's Medical Center Corporation | Fibrin-cell suspension for construction of new tissue |
US5516532A (en) | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
US5769899A (en) | 1994-08-12 | 1998-06-23 | Matrix Biotechnologies, Inc. | Cartilage repair unit |
CH689725A5 (en) | 1994-09-08 | 1999-09-30 | Franz Dr Sutter | Condyle prosthesis. |
US5824093A (en) | 1994-10-17 | 1998-10-20 | Raymedica, Inc. | Prosthetic spinal disc nucleus |
US5654166A (en) | 1994-11-09 | 1997-08-05 | Kurth; Gerhard P. | Process of preparing hormone-free bovine cartilage for dosage form |
US6110212A (en) | 1994-11-15 | 2000-08-29 | Kenton W. Gregory | Elastin and elastin-based materials |
US5585007A (en) | 1994-12-07 | 1996-12-17 | Plasmaseal Corporation | Plasma concentrate and tissue sealant methods and apparatuses for making concentrated plasma and/or tissue sealant |
US5632432A (en) | 1994-12-19 | 1997-05-27 | Ethicon Endo-Surgery, Inc. | Surgical instrument |
DE4445891A1 (en) | 1994-12-22 | 1996-06-27 | Boehringer Mannheim Gmbh | Recombinant proteinase from Clostridium histolyticum and its use for the isolation of cells and cell assemblies |
US6599515B1 (en) | 1995-01-16 | 2003-07-29 | Baxter International Inc. | Fibrin porous structure |
US6965014B1 (en) | 1996-01-16 | 2005-11-15 | Baxter International Inc. | Fibrin material and method for producing and using the same |
US5736396A (en) | 1995-01-24 | 1998-04-07 | Case Western Reserve University | Lineage-directed induction of human mesenchymal stem cell differentiation |
ES2150096T3 (en) | 1995-01-27 | 2000-11-16 | Coloplast As | A DRESSING. |
US5695998A (en) | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
US6485723B1 (en) | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
US6080194A (en) | 1995-02-10 | 2000-06-27 | The Hospital For Joint Disease Orthopaedic Institute | Multi-stage collagen-based template or implant for use in the repair of cartilage lesions |
US5879398A (en) | 1995-02-14 | 1999-03-09 | Zimmer, Inc. | Acetabular cup |
US20050186673A1 (en) | 1995-02-22 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US5782835A (en) | 1995-03-07 | 1998-07-21 | Innovasive Devices, Inc. | Apparatus and methods for articular cartilage defect repair |
US5840713A (en) | 1995-04-03 | 1998-11-24 | Weisz; Paul B. | Therapy for tissue membrane insufficiency |
US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
US5902785A (en) | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
US5655546A (en) | 1995-06-07 | 1997-08-12 | Halpern; Alan A. | Method for cartilage repair |
US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
JP4246795B2 (en) | 1995-07-25 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | β-type transforming growth factor crystals |
US5535810A (en) | 1995-07-28 | 1996-07-16 | Zimmer, Inc. | Cast orthopaedic implant and method of making same |
US5944755A (en) | 1995-09-15 | 1999-08-31 | Crosscart, Inc. | Articular cartilage xenografts |
US5782915A (en) | 1995-09-15 | 1998-07-21 | Stone; Kevin R. | Articular cartilage heterografts |
US6132674A (en) | 1995-10-12 | 2000-10-17 | Bristol-Myers Squibb Company | Method of making an orthopaedic implant having a porous surface |
WO1997017038A1 (en) | 1995-11-09 | 1997-05-15 | University Of Massachusetts | Tissue re-surfacing with hydrogel-cell compositions |
US6833408B2 (en) | 1995-12-18 | 2004-12-21 | Cohesion Technologies, Inc. | Methods for tissue repair using adhesive materials |
PT1704878E (en) | 1995-12-18 | 2013-07-17 | Angiodevice Internat Gmbh | Crosslinked polymer compositions and methods for their use |
US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
US5639280A (en) | 1996-02-02 | 1997-06-17 | Zimmer, Inc. | Constraining ring for a hip cup |
US5842477A (en) | 1996-02-21 | 1998-12-01 | Advanced Tissue Sciences, Inc. | Method for repairing cartilage |
US6087553A (en) | 1996-02-26 | 2000-07-11 | Implex Corporation | Implantable metallic open-celled lattice/polyethylene composite material and devices |
US5755791A (en) | 1996-04-05 | 1998-05-26 | Purdue Research Foundation | Perforated submucosal tissue graft constructs |
JP2000509307A (en) | 1996-04-30 | 2000-07-25 | メドトロニック,インコーポレイテッド | Method for producing autologous fibrin sealant |
DE19617369A1 (en) | 1996-04-30 | 1997-11-06 | Immuno Ag | Storage-stable fibrinogen preparations |
US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
EP0906128A1 (en) | 1996-05-28 | 1999-04-07 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
ES2210526T3 (en) | 1996-06-04 | 2004-07-01 | Centerpulse Biologics Inc. | CARTILAGO PRODUCTION PROCEDURE. |
DE69721265T2 (en) | 1996-07-01 | 2004-05-06 | Universiteit Utrecht | HYDROLYZABLE HYDROGELS FOR CONTROLLED RELEASE |
WO1998004681A2 (en) | 1996-07-25 | 1998-02-05 | Genzyme Corporation | Chondrocyte media formulations and culture procedures |
JP3492857B2 (en) | 1996-07-30 | 2004-02-03 | 京セラ株式会社 | Method for improving wear resistance of polyvinyl alcohol hydrogel |
US6666892B2 (en) | 1996-08-23 | 2003-12-23 | Cook Biotech Incorporated | Multi-formed collagenous biomaterial medical device |
US5989269A (en) | 1996-08-30 | 1999-11-23 | Vts Holdings L.L.C. | Method, instruments and kit for autologous transplantation |
US6120514A (en) | 1996-08-30 | 2000-09-19 | Vts Holdings, Llc | Method and kit for autologous transplantation |
US5827217A (en) | 1996-09-04 | 1998-10-27 | Silver; Frederick H. | Process and apparatus for harvesting tissue for processing tissue and process and apparatus for re-injecting processed tissue |
US5964805A (en) | 1997-02-12 | 1999-10-12 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
US5921987A (en) | 1996-09-13 | 1999-07-13 | Depuy Orthopaedic Technology, Inc. | Articular cartilage transplant instrument set |
IT1284550B1 (en) | 1996-09-18 | 1998-05-21 | Flavio Tarantino | PROCEDURE FOR THE PREPARATION OF AUTOLOGOUS FIBRIN GLUE FOR SURGICAL USE |
NL1004276C2 (en) | 1996-10-15 | 1998-04-20 | Willem Marie Ysebaert | Methods for manufacturing skin islets, for moving skin or islets, for spreading skin isles and applying them to a burn, as well as a holder, cutting frame, cutting table, counter carrier, clamping member, membrane, transporter and spreader for use in such methods. |
US5919702A (en) | 1996-10-23 | 1999-07-06 | Advanced Tissue Science, Inc. | Production of cartilage tissue using cells isolated from Wharton's jelly |
DE59711812D1 (en) | 1996-11-19 | 2004-09-02 | Roche Diagnostics Gmbh | RECOMBINANT COLLAGENASE TYPE I FROM CLOSTRIDIUM HISTOLYTICUM AND THEIR USE FOR INSULATING CELLS AND CELL ASSOCIATIONS |
US5928945A (en) | 1996-11-20 | 1999-07-27 | Advanced Tissue Sciences, Inc. | Application of shear flow stress to chondrocytes or chondrocyte stem cells to produce cartilage |
DE19648744A1 (en) | 1996-11-25 | 1998-05-28 | Basf Ag | Process for the preparation of a polymer dispersion by radical aqueous emulsion polymerization with a continuously produced aqueous monomer emulsion |
US5830741A (en) | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
FR2757770B1 (en) | 1996-12-30 | 1999-02-26 | Inoteb | PROCESS FOR THE PREPARATION OF A BIOLOGICAL GLUE CAPABLE OF COAGULATING BY SIMPLE ADDITION OF CALCIUM IONS |
US8882847B2 (en) | 2001-05-25 | 2014-11-11 | Conformis, Inc. | Patient selectable knee joint arthroplasty devices |
EP1010356B1 (en) | 1997-01-26 | 2003-04-16 | Horst Mosshammer Von Mosshaim | Table top model hot plate or warming plate appliance |
DE19708703C2 (en) | 1997-02-24 | 2002-01-24 | Co Don Ag | Surgical cutlery |
US6152142A (en) | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
GB9704749D0 (en) | 1997-03-07 | 1997-04-23 | Univ London | Tissue Implant |
US6733515B1 (en) | 1997-03-12 | 2004-05-11 | Neomend, Inc. | Universal introducer |
DE19713011C2 (en) * | 1997-03-27 | 1999-10-21 | Friadent Gmbh | Foil for medical technology |
WO1998044874A1 (en) | 1997-04-04 | 1998-10-15 | Barnes-Jewish Hospital | Neocartilage and methods of use |
US6224893B1 (en) | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
US6979307B2 (en) | 1997-06-24 | 2005-12-27 | Cascade Medical Enterprises Llc | Systems and methods for preparing autologous fibrin glue |
IT1292410B1 (en) | 1997-06-24 | 1999-02-08 | Roberto Beretta | READY-TO-USE CONTAINER TO OBTAIN AUTOLOGOUS FIBRIN GLUE |
US6107085A (en) | 1997-07-11 | 2000-08-22 | Corning Incorporated | Self contained cell growth system |
ZA987019B (en) | 1997-08-06 | 1999-06-04 | Focal Inc | Hemostatic tissue sealants |
US6110209A (en) | 1997-08-07 | 2000-08-29 | Stone; Kevin R. | Method and paste for articular cartilage transplantation |
US6511958B1 (en) | 1997-08-14 | 2003-01-28 | Sulzer Biologics, Inc. | Compositions for regeneration and repair of cartilage lesions |
DE69714035T2 (en) | 1997-08-14 | 2003-03-06 | Sulzer Innotec Ag | Composition and device for repairing cartilage tissue in vivo consisting of nanocapsules with osteoinductive and / or chondroinductive factors |
WO1999010023A2 (en) | 1997-08-22 | 1999-03-04 | Direct Therapeutics, Inc. | An apparatus for preventing loss of a composition during a medical procedure |
JPH1178498A (en) | 1997-09-17 | 1999-03-23 | Toyota Autom Loom Works Ltd | Coolant circulating method and coolant circulating circuit |
US6041723A (en) | 1997-09-26 | 2000-03-28 | Peterson; Graham | Portable collapsible self-assembling desk |
US20050186283A1 (en) | 1997-10-10 | 2005-08-25 | Ed. Geistlich Soehne Ag Fuer Chemistrie Industrie | Collagen carrier of therapeutic genetic material, and method |
US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
US20030099620A1 (en) | 1997-10-30 | 2003-05-29 | The General Hospital Corporation | Bonding of cartilaginous matrices using isolated chondrocytes |
US6080579A (en) | 1997-11-26 | 2000-06-27 | Charlotte-Mecklenburg Hospital Authority | Method for producing human intervertebral disc cells |
US5964752A (en) | 1998-02-02 | 1999-10-12 | Stone; Kevin R. | Articular cartilage surface shaping apparatus and method |
US6437018B1 (en) | 1998-02-27 | 2002-08-20 | Musculoskeletal Transplant Foundation | Malleable paste with high molecular weight buffered carrier for filling bone defects |
US6143214A (en) | 1998-03-09 | 2000-11-07 | Board Of Regents Of The University Of Texas System | Mixing and dispensing system for rapidly polymerizing materials |
DE69903800T2 (en) | 1998-03-18 | 2003-10-02 | Massachusetts Inst Technology | VASCULARIZED PERFUNDED ARRANGEMENTS FOR MICRO TISSUE AND MICROORGANES |
US6471958B2 (en) | 1998-03-24 | 2002-10-29 | University Of North Texas Health Science Center | Non-contracting tissue equivalent |
AU3118499A (en) | 1998-04-03 | 1999-10-25 | Beth Israel Deaconess Medical Center | Soft tissue reconstructor and method of use |
US6378527B1 (en) | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
US6637437B1 (en) | 1998-04-08 | 2003-10-28 | Johns Hopkins University | Cell-culture and polymer constructs |
US6886568B2 (en) | 1998-04-08 | 2005-05-03 | The Johns Hopkins University | Method for fabricating cell-containing implants |
US20040044408A1 (en) | 1998-04-08 | 2004-03-04 | Hungerford David S. | Cell-culture and polymer constructs |
EP2133725B1 (en) | 1998-04-21 | 2018-06-06 | University of Connecticut | Fabrication method for nanofabrication using multi-photon excitation |
KR20010014278A (en) | 1998-04-30 | 2001-02-26 | 요트.게.아. 롤페즈 | Code division multiple access transmitter and receiver |
US6132465A (en) | 1998-06-04 | 2000-10-17 | Raymedica, Inc. | Tapered prosthetic spinal disc nucleus |
US6083383A (en) | 1998-06-25 | 2000-07-04 | Huang; Xun Yang | Apparatus for production of fibrin ogen or fibrin glue |
US6086593A (en) | 1998-06-30 | 2000-07-11 | Bonutti; Peter M. | Method and apparatus for use in operating on a bone |
US6045990A (en) | 1998-07-09 | 2000-04-04 | Baust; John M. | Inclusion of apoptotic regulators in solutions for cell storage at low temperature |
WO2000006216A1 (en) | 1998-07-27 | 2000-02-10 | Focal, Inc. | Universal modular surgical applicator systems |
US6274090B1 (en) | 1998-08-05 | 2001-08-14 | Thermogenesis Corp. | Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
AU5132199A (en) | 1998-08-13 | 2000-03-06 | Warner-Lambert Company | Electroporation buffer with cryprotective capabilities |
AU771701B2 (en) | 1998-08-14 | 2004-04-01 | Genzyme Corporation | Methods, instruments and materials for chondrocyte cell transplantation |
US6551355B1 (en) | 1998-08-14 | 2003-04-22 | Cambridge Scientific, Inc. | Tissue transplant coated with biocompatible biodegradable polymer |
US6099531A (en) | 1998-08-20 | 2000-08-08 | Bonutti; Peter M. | Changing relationship between bones |
JP2004502401A (en) | 1998-09-18 | 2004-01-29 | マサチューセッツ インスティテュート オブ テクノロジー | Use of growth factors and hormones for mammalian cell expansion and tissue engineering |
US6140123A (en) | 1998-10-07 | 2000-10-31 | Cedars-Sinai Medical Center | Method for conditioning and cryopreserving cells |
US20030114936A1 (en) | 1998-10-12 | 2003-06-19 | Therics, Inc. | Complex three-dimensional composite scaffold resistant to delimination |
WO2000029484A1 (en) | 1998-11-17 | 2000-05-25 | Biocomposites, Llc | Process for preparing high density mechanically resistant insoluble collagen material in pure and combined forms |
US7276235B2 (en) | 1998-11-18 | 2007-10-02 | Zlb Behring Gmbh | Tissue glue with improved antiadhesive properties |
US6200330B1 (en) | 1998-11-23 | 2001-03-13 | Theodore V. Benderev | Systems for securing sutures, grafts and soft tissue to bone and periosteum |
DE19855890A1 (en) | 1998-12-03 | 2000-06-08 | Nerlich Michael | Porous composite matrix, its production and use |
WO2000048837A1 (en) | 1999-02-16 | 2000-08-24 | Dek Printing Machines Limited | Apparatus and method for depositing a viscous material |
US6264659B1 (en) | 1999-02-22 | 2001-07-24 | Anthony C. Ross | Method of treating an intervertebral disk |
US6436143B1 (en) | 1999-02-22 | 2002-08-20 | Anthony C. Ross | Method and apparatus for treating intervertebral disks |
DE19908628A1 (en) | 1999-02-27 | 2000-08-31 | Lurgi Zimmer Ag | Catalyst, process for its preparation and use of the catalyst |
AU3556400A (en) | 1999-03-17 | 2000-10-04 | Novartis Ag | Pharmaceutical compositions |
US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
US6110210A (en) | 1999-04-08 | 2000-08-29 | Raymedica, Inc. | Prosthetic spinal disc nucleus having selectively coupled bodies |
US6428576B1 (en) | 1999-04-16 | 2002-08-06 | Endospine, Ltd. | System for repairing inter-vertebral discs |
US6287340B1 (en) | 1999-05-14 | 2001-09-11 | Trustees Of Tufts College | Bioengineered anterior cruciate ligament |
US6645947B1 (en) | 1999-05-20 | 2003-11-11 | Chitogenics, Inc. | Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins |
MXPA01012234A (en) | 1999-05-28 | 2002-07-30 | Henkel Kgaa | Post-passivation of a phosphatized metal surface. |
US6472162B1 (en) | 1999-06-04 | 2002-10-29 | Thermogenesis Corp. | Method for preparing thrombin for use in a biological glue |
DE19926083A1 (en) | 1999-06-08 | 2000-12-14 | Universitaetsklinikum Freiburg | Biological joint construct |
US20040059416A1 (en) | 1999-06-22 | 2004-03-25 | Murray Martha M. | Biologic replacement for fibrin clot |
US6333029B1 (en) | 1999-06-30 | 2001-12-25 | Ethicon, Inc. | Porous tissue scaffoldings for the repair of regeneration of tissue |
US6632651B1 (en) | 1999-07-06 | 2003-10-14 | Ramot At Tel Aviv University Ltd. | Tissue maintenance system that applies rhythmic pulses of pressure |
AU7004900A (en) | 1999-07-21 | 2001-02-05 | Imedex Biomateriaux | Adhesive protein foam for surgical and/or therapeutic uses |
ATE290353T1 (en) | 1999-07-28 | 2005-03-15 | Interface Biotech As | IN VITRO HEALING OF BONE AND/OR CARTILAGE DAMAGE |
GB9918884D0 (en) | 1999-08-10 | 1999-10-13 | Novarticulate Bv | Method and apparatus for delivering cement to bones |
US6425919B1 (en) | 1999-08-18 | 2002-07-30 | Intrinsic Orthopedics, Inc. | Devices and methods of vertebral disc augmentation |
US6280993B1 (en) | 1999-08-24 | 2001-08-28 | Ichiro Yamato | Gene encoding class I collagenase |
US6620169B1 (en) | 1999-08-26 | 2003-09-16 | Spineology Group, Llc. | Tools and method for processing and injecting bone graft |
US6322563B1 (en) | 1999-09-17 | 2001-11-27 | Genzyme Corporation | Small tissue and membrane fixation apparatus and methods for use thereof |
GB9922872D0 (en) * | 1999-09-28 | 1999-12-01 | Depuy Int Ltd | Bone tissue repair kit |
US6528052B1 (en) | 2000-09-29 | 2003-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Method for in vivo ex vivo and in vitro repair and regeneration of cartilage and collagen and bone remodeling |
US6579538B1 (en) | 1999-12-22 | 2003-06-17 | Acell, Inc. | Tissue regenerative compositions for cardiac applications, method of making, and method of use thereof |
US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
US6425704B2 (en) | 2000-01-07 | 2002-07-30 | Closure Medical Corporation | Adhesive applicators with improved applicator tips |
US6626859B2 (en) | 2000-01-18 | 2003-09-30 | Coraflo Ltd. | High performance cannulas |
US6447514B1 (en) | 2000-03-07 | 2002-09-10 | Zimmer | Polymer filled hip fracture fixation device |
US6332894B1 (en) | 2000-03-07 | 2001-12-25 | Zimmer, Inc. | Polymer filled spinal fusion cage |
DE10013223C2 (en) | 2000-03-13 | 2002-07-18 | Co Don Ag | Process for the in vitro production of three-dimensional, vital cartilage or bone tissue and its use as a transplant material |
US6652883B2 (en) | 2000-03-13 | 2003-11-25 | Biocure, Inc. | Tissue bulking and coating compositions |
US6632246B1 (en) | 2000-03-14 | 2003-10-14 | Chondrosite, Llc | Cartilage repair plug |
US6626945B2 (en) | 2000-03-14 | 2003-09-30 | Chondrosite, Llc | Cartilage repair plug |
US6533817B1 (en) | 2000-06-05 | 2003-03-18 | Raymedica, Inc. | Packaged, partially hydrated prosthetic disc nucleus |
JP2004513676A (en) | 2000-06-22 | 2004-05-13 | オースティン,サム,エル | Bioadhesive composition and its production and use |
US6921532B1 (en) | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
DE60141653D1 (en) | 2000-07-21 | 2010-05-06 | Spineology Group Llc | A STRONG, POROUS NET BAG DEVICE AND ITS USE IN BONE SURGERY |
US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
US7186419B2 (en) | 2000-08-25 | 2007-03-06 | Contura Sa | Polyacrylamide hydrogel for arthritis |
MY130475A (en) | 2000-08-25 | 2007-06-29 | Contura As | Polyacrylamide hydrogel and its use as an endoprosthesis |
US6620196B1 (en) | 2000-08-30 | 2003-09-16 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
EP1333870A2 (en) | 2000-09-20 | 2003-08-13 | Regeneration Technologies, Inc. | Method of preparing and processing transplant tissue |
US6610033B1 (en) | 2000-10-13 | 2003-08-26 | Incept, Llc | Dual component medicinal polymer delivery system and methods of use |
DE10061195B4 (en) | 2000-12-08 | 2004-12-02 | 3M Espe Ag | Use of impression materials for the production of treatment devices |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6890295B2 (en) | 2002-10-31 | 2005-05-10 | Medtronic, Inc. | Anatomical space access tools and methods |
US7666192B2 (en) | 2001-02-16 | 2010-02-23 | Kci Licensing, Inc. | Skin grafting devices and methods |
US7651507B2 (en) | 2003-03-03 | 2010-01-26 | Kci Licensing, Inc. | Tissue processing system |
US7544196B2 (en) | 2001-02-20 | 2009-06-09 | Orthovita, Inc. | System and kit for delivery of restorative materials |
US6773713B2 (en) | 2001-02-23 | 2004-08-10 | University Of Massachusetts | Injection molding of living tissues |
US6743232B2 (en) | 2001-02-26 | 2004-06-01 | David W. Overaker | Tissue scaffold anchor for cartilage repair |
IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
US20040151705A1 (en) | 2002-03-22 | 2004-08-05 | Shuichi Mizuno | Neo-cartilage constructs and a method for preparation thereof |
WO2002080991A2 (en) | 2001-04-09 | 2002-10-17 | Medtronic, Inc. | System for the production of autologous platelet gel |
EP1423093A4 (en) | 2001-04-23 | 2005-11-30 | Wisconsin Alumni Res Found | Bifunctional-modified hydrogels |
DE60121826T2 (en) | 2001-05-09 | 2007-02-22 | Baxter International Inc., Deerfield | FIBRIN MATERIAL AND METHOD FOR ITS MANUFACTURE AND USE |
KR20020088848A (en) | 2001-05-21 | 2002-11-29 | (주)코아바이오텍 | Cell Culture Tube and Multiple Roller Tube Cell Culture System Using The Same |
US20020183858A1 (en) * | 2001-06-05 | 2002-12-05 | Contiliano Joseph H. | Attachment of absorbable tissue scaffolds to scaffold fixation devices |
AU2002345691C1 (en) | 2001-06-13 | 2008-07-24 | Massachusetts Institute Of Technology | In vivo bioreactors |
KR20020095842A (en) | 2001-06-16 | 2002-12-28 | 삼성전자 주식회사 | Ashing apparatus of semiconductor |
US6626950B2 (en) | 2001-06-28 | 2003-09-30 | Ethicon, Inc. | Composite scaffold with post anchor for the repair and regeneration of tissue |
US7083964B2 (en) | 2001-07-02 | 2006-08-01 | Nordmark Arzneimittel Gmbh & Co. Kg | Method for purifying enzymes from clostridium histolyticum using multi-stage chromatography |
FR2827290B1 (en) | 2001-07-13 | 2004-07-09 | Pierre Jouan Biotechnologies Sa | METHOD FOR OBTAINING A PROTEIN FRACTION ENRICHED IN ACTIVATED FORM TGF-BETA, PROTEIN FRACTION AND THERAPEUTIC APPLICATIONS |
IL144446A0 (en) | 2001-07-19 | 2002-05-23 | Prochon Biotech Ltd | Plasma protein matrices and methods for their preparation |
JP4015618B2 (en) | 2001-08-25 | 2007-11-28 | コンチュラ ソシエテ アノニム | Polymer hydrogels used in prosthesis, use for making polymer hydrogel prostheses and powder polyacrylamide hydrogels |
JP4394441B2 (en) | 2001-10-02 | 2010-01-06 | レックス メディカル リミテッド パートナーシップ | Spinal implant |
AU2002362932B2 (en) | 2001-10-18 | 2008-06-19 | Lifecell Corporation | Remodeling of tissues and organs |
US20030134032A1 (en) | 2001-11-16 | 2003-07-17 | Hassan Chaouk | Methods for initiating in situ formation of hydrogels |
US20020106625A1 (en) | 2002-02-07 | 2002-08-08 | Hung Clark T. | Bioreactor for generating functional cartilaginous tissue |
US7042803B2 (en) | 2002-02-08 | 2006-05-09 | Input/Output Inc. | Marine seismic source towing apparatus and method |
AU2002233088A1 (en) | 2002-02-15 | 2003-09-04 | Ocean Nutrition Canada Limited | Shark cartilage extracts and use thereof for immunomodulation |
US6740186B2 (en) | 2002-02-20 | 2004-05-25 | Zimmer Technology, Inc. | Method of making an orthopeadic implant having a porous metal surface |
TWI290055B (en) | 2002-03-14 | 2007-11-21 | Tissuetech Inc | Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes |
US7537780B2 (en) | 2002-03-22 | 2009-05-26 | Histogenics Corporation | Method for preparing and implanting a cartilage construct to treat cartilage lesions |
US20030187515A1 (en) | 2002-03-26 | 2003-10-02 | Hariri Robert J. | Collagen biofabric and methods of preparing and using the collagen biofabric |
AU2003228808A1 (en) | 2002-05-02 | 2003-11-17 | Regents Of The University Of Minnesota | Fibrin-based biomatrix |
GB0211963D0 (en) | 2002-05-24 | 2002-07-03 | British American Tobacco Co | An exposure device |
US6797006B2 (en) | 2002-06-18 | 2004-09-28 | Zimmer Technology, Inc. | Porous unicondylar knee |
DE10261126A1 (en) | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Storage-stable, liquid fibrinogen formulation |
US7494460B2 (en) | 2002-08-21 | 2009-02-24 | Medtronic, Inc. | Methods and apparatus providing suction-assisted tissue engagement through a minimally invasive incision |
US20060128016A1 (en) | 2002-08-23 | 2006-06-15 | Yasuo Tokushima | Fibrin-containing composition |
US20040126881A1 (en) | 2002-09-06 | 2004-07-01 | Vincent Ronfard | Fibrin cell supports and methods of use thereof |
US20040054414A1 (en) | 2002-09-18 | 2004-03-18 | Trieu Hai H. | Collagen-based materials and methods for augmenting intervertebral discs |
US7744651B2 (en) | 2002-09-18 | 2010-06-29 | Warsaw Orthopedic, Inc | Compositions and methods for treating intervertebral discs with collagen-based materials |
US7666134B2 (en) | 2002-09-28 | 2010-02-23 | Kci Licensing, Inc. | System and method for transplantation of dermal tissue |
AU2003265103A1 (en) | 2002-09-30 | 2004-04-19 | Bioland Ltd. | Dermal substitute consisting of amnion and biodegradable polymer, the preparation method and the use thereof |
US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
IL153699A (en) | 2002-12-26 | 2008-11-26 | Prochon Biotech Ltd | Bone graft composite |
US7115100B2 (en) | 2002-11-15 | 2006-10-03 | Ethicon, Inc. | Tissue biopsy and processing device |
US6921633B2 (en) | 2002-11-18 | 2005-07-26 | Biolife Solutions Incorporated | Methods and compositions for the preservation of cells, tissues or organs in the vitreous state |
AU2004212942A1 (en) | 2003-02-14 | 2004-09-02 | Depuy Spine, Inc. | In-situ formed intervertebral fusion device |
WO2004078035A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Expression profiles for breast cancer and methods of use |
GB0304799D0 (en) | 2003-03-03 | 2003-04-09 | Glaxosmithkline Biolog Sa | Novel method |
US20040175690A1 (en) | 2003-03-03 | 2004-09-09 | Kci Licensing, Inc. | Tissue harvesting device and method |
US20050064042A1 (en) | 2003-04-29 | 2005-03-24 | Musculoskeletal Transplant Foundation | Cartilage implant plug with fibrin glue and method for implantation |
US7067123B2 (en) | 2003-04-29 | 2006-06-27 | Musculoskeletal Transplant Foundation | Glue for cartilage repair |
US20050222687A1 (en) | 2004-04-02 | 2005-10-06 | Gordana Vunjak-Novakovic | Cartilage implant assembly and method for implantation |
US20050123520A1 (en) * | 2003-05-05 | 2005-06-09 | Eavey Roland D. | Generation of living tissue in vivo using a mold |
US7901457B2 (en) | 2003-05-16 | 2011-03-08 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US20090291112A1 (en) | 2003-05-16 | 2009-11-26 | Truncale Katherine G | Allograft osteochondral plug combined with cartilage particle mixture |
NZ544050A (en) * | 2003-06-11 | 2009-03-31 | Osteotech Inc | Osteoimplants and methods for their manufacture |
US20070077236A1 (en) | 2003-06-12 | 2007-04-05 | Interface Biotech A/S | Method for cell implantation |
US20050124038A1 (en) | 2003-07-14 | 2005-06-09 | Pharmacia Corporation | Transfection of cartilage and matrices thereof in vitro |
ATE528026T1 (en) | 2003-07-31 | 2011-10-15 | Yukihide Iwamoto | METHOD FOR PRODUCING AN ARTIFICIAL JOINT |
GB0318125D0 (en) | 2003-08-01 | 2003-09-03 | Inst Of Cancer Res The | Apparatus and methods for tissue preparation |
US8043614B2 (en) | 2004-03-09 | 2011-10-25 | Ahlfors Jan-Eric W | Autogenic living scaffolds and living tissue matrices: methods and uses thereof |
US7897384B2 (en) | 2003-09-08 | 2011-03-01 | Ethicon, Inc. | Chondrocyte therapeutic delivery system |
EP1669440B1 (en) | 2003-09-19 | 2009-12-02 | Keio University | Composition for coating support for preparation of cell sheet, support for preparation of cell sheet and process for producing cell sheet |
US7375077B2 (en) | 2003-09-19 | 2008-05-20 | The Board Of Trustees Of The University Of Illinois | In vivo synthesis of connective tissues |
EP1529543A1 (en) | 2003-11-04 | 2005-05-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of a hydrogel for culturing chondrocytes |
WO2005046746A2 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US8673021B2 (en) | 2003-11-26 | 2014-03-18 | Depuy Mitek, Llc | Arthroscopic tissue scaffold delivery device |
US7901461B2 (en) | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
US7753955B2 (en) * | 2003-12-10 | 2010-07-13 | Cellular Bioengineering, Inc. | Methods and composition for soft tissue feature reconstruction |
EP1722834B1 (en) | 2003-12-22 | 2012-06-27 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring crosslinked protein backbone |
US20050137600A1 (en) | 2003-12-23 | 2005-06-23 | Jacobs Andrew M. | Articular cartilage repair implant delivery device and method of use |
KR100531922B1 (en) | 2003-12-23 | 2005-11-29 | 주식회사 셀론텍 | a composition for cartilage therapeutics and a using method thereof |
US6997381B2 (en) | 2003-12-24 | 2006-02-14 | Michael Arnouse | Dual-sided smart card reader |
US7500947B2 (en) | 2004-01-29 | 2009-03-10 | Cannonflow, Inc. | Atraumatic arthroscopic instrument sheath |
US7445596B2 (en) | 2004-01-29 | 2008-11-04 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
US7435214B2 (en) | 2004-01-29 | 2008-10-14 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
US7413542B2 (en) | 2004-01-29 | 2008-08-19 | Cannuflow, Inc. | Atraumatic arthroscopic instrument sheath |
US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
US20060275273A1 (en) | 2004-02-20 | 2006-12-07 | Seyedin Mitchell S | Intervertebral Disc Repair, Methods and Devices Therefor |
AU2005225403A1 (en) | 2004-03-03 | 2005-10-06 | Schwartz Biomedical, Llc | Articular cartilage fixation device and method |
US20050196460A1 (en) | 2004-03-08 | 2005-09-08 | Malinin Theodore I. | Particulate cartilage compositions, processes for their preparation and methods for regenerating cartilage |
US20050209602A1 (en) | 2004-03-22 | 2005-09-22 | Disc Dynamics, Inc. | Multi-stage biomaterial injection system for spinal implants |
US20070292945A1 (en) | 2004-03-25 | 2007-12-20 | Lin Wenglong R | Cell Culture Apparatus and Methods |
WO2005113749A2 (en) | 2004-05-14 | 2005-12-01 | Becton, Dickinson And Company | Stem cell populations and methods of use |
US20050288796A1 (en) | 2004-06-23 | 2005-12-29 | Hani Awad | Native soft tissue matrix for therapeutic applications |
JP4857268B2 (en) | 2004-06-29 | 2012-01-18 | バイオキュア・インコーポレーテッド | Spinal disc nucleus pulposus graft |
WO2006017176A2 (en) | 2004-07-09 | 2006-02-16 | William Marsh Rice University | Scaffoldless constructs for tissue engineering of articular cartilage |
US8512730B2 (en) | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
US8357147B2 (en) | 2005-08-17 | 2013-01-22 | Spinal Restoration, Inc. | Method for repairing intervertebral discs |
US8419722B2 (en) | 2004-10-29 | 2013-04-16 | Spinal Restoration, Inc. | Apparatus and method for injection of fibrin sealant in spinal applications |
US20090181092A1 (en) | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods for Treating Joints and Discs with a Carrier Matrix and Cells |
US20090181892A1 (en) | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods and kits for treating joints and soft tissues |
US20070213660A1 (en) | 2004-10-29 | 2007-09-13 | Mark Richards | Fibrin sealant delivery device including pressure monitoring, and method and kits thereof |
US20090181093A1 (en) | 2004-07-16 | 2009-07-16 | Spinal Restoration, Inc. | Methods for treating soft tissue damage associated with a surgical procedure |
GB0421298D0 (en) | 2004-09-24 | 2004-10-27 | Univ Bristol | Cellular bandage |
US7273756B2 (en) | 2004-10-01 | 2007-09-25 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
US8017394B2 (en) | 2004-10-01 | 2011-09-13 | Isto Technologies, Inc. | Method for chondrocyte expansion with phenotype retention |
US20060078872A1 (en) | 2004-10-12 | 2006-04-13 | Atsushi Taguchi | Cell-preservation liquid |
US7837740B2 (en) | 2007-01-24 | 2010-11-23 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US20090149893A1 (en) | 2007-12-05 | 2009-06-11 | Semler Eric J | Cancellous Bone Implant for Cartilage Repair |
AU2005301150B2 (en) | 2004-10-18 | 2011-02-03 | Covidien Lp | Apparatus for applying wound treatment material using tissue-penetrating needles |
US20060111778A1 (en) | 2004-10-29 | 2006-05-25 | Michalow Alexander E | Methods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway |
US9981063B2 (en) | 2004-11-24 | 2018-05-29 | Mayo Foundation For Medical Education And Research | Biosynthetic composite for osteochondral defect repair |
WO2006061824A2 (en) | 2004-12-06 | 2006-06-15 | Prochon Biotech Limited | Chondrocyte-based implant for the delivery of therapeutic agents |
WO2006101548A2 (en) | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060153815A1 (en) | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
CA2594396A1 (en) | 2005-01-14 | 2006-07-20 | Arblast Co., Ltd. | Sheet-shaped composition utilizing amnion and method of preparing the same |
WO2006090372A2 (en) | 2005-02-22 | 2006-08-31 | I.M.T. Interface Multigrad Technology Ltd. | Preserved viable cartilage, method for its preservation, and system and devices used therefor |
JP2006230749A (en) | 2005-02-25 | 2006-09-07 | Kaneka Corp | Material for fixing prosthesis to cartilage tissue |
US20060251631A1 (en) | 2005-05-05 | 2006-11-09 | Isto Technologies, Inc. | Treatment of joint disease, methods and apparatuses therefor |
US20060264966A1 (en) | 2005-05-12 | 2006-11-23 | Med Institute, Inc. | Vertebroplasty leak prevention sleeve and method |
JP4044579B2 (en) | 2005-08-02 | 2008-02-06 | 株式会社Pgリサーチ | Artificial cartilage tissue |
EP1916964A4 (en) | 2005-08-26 | 2015-11-04 | Zimmer Inc | Implants and methods for repair, replacement and treatment of joint disease |
KR20080065606A (en) | 2005-09-02 | 2008-07-14 | 인터페이스 바이오텍 에이/에스 | A method for cell implantation |
US8158141B2 (en) | 2005-11-09 | 2012-04-17 | Paul Hong-Dze Chen | Cell transplant device for treatment of corneal wound |
US20100209397A1 (en) | 2005-11-10 | 2010-08-19 | Carticure Ltd. | Method for non-autologous cartilage regeneration |
PL1788077T3 (en) | 2005-11-18 | 2017-03-31 | Lifescan, Inc. | A method for creating cell clusters |
CA2631520A1 (en) | 2005-12-07 | 2007-06-14 | Isto Technologies, Inc. | Cartilage repair methods |
US8524885B2 (en) | 2006-03-07 | 2013-09-03 | Prochon Biotech Ltd. | Hydrazido derivatives of hyaluronic acid |
EP2007875A4 (en) | 2006-04-05 | 2009-12-16 | Univ Rice William M | Dermis-derived cells for tissue engineering applications |
US20070250164A1 (en) | 2006-04-21 | 2007-10-25 | Biomet Manufacturing Corp. | Method for grafting whole superficial articular cartilage |
US20070299517A1 (en) | 2006-06-21 | 2007-12-27 | Howmedica Osteonics Corp. | Articular cartilage implant |
US8449622B2 (en) | 2006-09-11 | 2013-05-28 | Warsaw Orthopedic, Inc. | Multi-phase osteochondral implantable device |
US20080154233A1 (en) | 2006-12-20 | 2008-06-26 | Zimmer Orthobiologics, Inc. | Apparatus for delivering a biocompatible material to a surgical site and method of using same |
US7720533B2 (en) | 2006-12-20 | 2010-05-18 | Zimmer Orthobiologicals, Inc. | Apparatus and method for delivering a biocompatible material to a surgical site |
US8163549B2 (en) | 2006-12-20 | 2012-04-24 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
JP5295121B2 (en) | 2006-12-22 | 2013-09-18 | ラボラトワール・メディドム・エス・アー | In situ system for endoarticular cartilage and bone tissue repair |
WO2008081463A2 (en) | 2007-01-04 | 2008-07-10 | Hepacore Ltd. | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof |
US20090012629A1 (en) | 2007-04-12 | 2009-01-08 | Isto Technologies, Inc. | Compositions and methods for tissue repair |
CA2717725A1 (en) | 2008-03-05 | 2009-09-11 | Musculoskeletal Transplant Foundation | Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles |
US20100168856A1 (en) | 2008-12-31 | 2010-07-01 | Howmedica Osteonics Corp. | Multiple piece tissue void filler |
WO2010083051A2 (en) | 2009-01-15 | 2010-07-22 | ProChon Biotech, Ltd. | Cartilage particle tissue mixtures optionally combined with a cancellous construct |
US20140178343A1 (en) | 2012-12-21 | 2014-06-26 | Jian Q. Yao | Supports and methods for promoting integration of cartilage tissue explants |
-
2008
- 2008-04-11 US US12/101,553 patent/US20090012629A1/en not_active Abandoned
- 2008-04-11 AU AU2008240191A patent/AU2008240191B2/en active Active
- 2008-04-11 WO PCT/US2008/060078 patent/WO2008128075A1/en active Application Filing
- 2008-04-11 EP EP08745639.8A patent/EP2134297B1/en active Active
- 2008-04-11 CA CA2684040A patent/CA2684040C/en active Active
-
2011
- 2011-12-15 US US13/327,265 patent/US9138318B2/en active Active
Patent Citations (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3302289A (en) * | 1963-10-21 | 1967-02-07 | Lawrence A Spaulding | Impression and bite tray for dentistry |
US5002582A (en) * | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
US4566138A (en) * | 1983-03-08 | 1986-01-28 | Zimmer, Inc. | Prosthetic device with spacers |
US4911720A (en) * | 1983-03-10 | 1990-03-27 | Collier John P | Particular surface replacement prosthesis |
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
US4641651A (en) * | 1983-09-22 | 1987-02-10 | Card George W | Cartilage punch and modified prosthesis in tympanoplasty |
US4640834A (en) * | 1984-03-09 | 1987-02-03 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Method of inactivating reproducible filterable pathogens in blood products as well as a method of producing blood products |
US4818633A (en) * | 1985-11-14 | 1989-04-04 | Imperial Chemical Industries Plc | Fibre-reinforced metal matrix composites |
US5002071A (en) * | 1987-04-03 | 1991-03-26 | Research Development Foundation | Injectable soft tissue augmentation materials from the placenta and their method of manufacture |
US5612028A (en) * | 1988-02-17 | 1997-03-18 | Genethics Limited | Method of regenerating or replacing cartilage tissue using amniotic cells |
US4904259A (en) * | 1988-04-29 | 1990-02-27 | Samuel Itay | Compositions and methods for repair of cartilage and bone |
US5080674A (en) * | 1988-09-08 | 1992-01-14 | Zimmer, Inc. | Attachment mechanism for securing an additional portion to an implant |
US5189148A (en) * | 1989-07-07 | 1993-02-23 | Takeda Chemical Industries, Inc. | Stabilized fgf composition and production thereof |
US5290558A (en) * | 1989-09-21 | 1994-03-01 | Osteotech, Inc. | Flowable demineralized bone powder composition and its use in bone repair |
US4997445A (en) * | 1989-12-08 | 1991-03-05 | Zimmer, Inc. | Metal-backed prosthetic implant with enhanced bonding of polyethylene portion to metal base |
US4997444A (en) * | 1989-12-28 | 1991-03-05 | Zimmer, Inc. | Implant having varying modulus of elasticity |
US20030009147A1 (en) * | 1990-06-28 | 2003-01-09 | Bonutti Peter M. | Biodegradable sac and method of using same |
US6503267B2 (en) * | 1990-06-28 | 2003-01-07 | Peter M. Bonutti | Surgical devices assembled using heat bondable materials |
US6174313B1 (en) * | 1990-06-28 | 2001-01-16 | Peter M. Bonutti | Apparatus and method for tissue removal |
US6990982B1 (en) * | 1990-06-28 | 2006-01-31 | Bonutti Ip, Llc | Method for harvesting and processing cells from tissue fragments |
US5198308A (en) * | 1990-12-21 | 1993-03-30 | Zimmer, Inc. | Titanium porous surface bonded to a cobalt-based alloy substrate in an orthopaedic implant device |
US5864016A (en) * | 1991-06-20 | 1999-01-26 | Immuno Aktiengesellschaft | Blood product, a method of producing the same and a method of determining the virus inactivation capacity of an inactivation treatment |
US5092887A (en) * | 1991-08-12 | 1992-03-03 | El Gendler | Artificial ligament produced from demineralized bone for the replacement and augmentation of ligaments, tendons and other fibrous connective tissue |
US6503277B2 (en) * | 1991-08-12 | 2003-01-07 | Peter M. Bonutti | Method of transplanting human body tissue |
US5281422A (en) * | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
US5482929A (en) * | 1991-12-26 | 1996-01-09 | Kaken Pharmaceutical Co., Ltd. | Composition of stabilized fibroblast growth factor |
US5282861A (en) * | 1992-03-11 | 1994-02-01 | Ultramet | Open cell tantalum structures for cancellous bone implants and cell and tissue receptors |
US5387243A (en) * | 1992-11-23 | 1995-02-07 | Zimmer, Inc. | Method for converting a cementable implant to a press fit implant |
US5723011A (en) * | 1992-12-21 | 1998-03-03 | Zimmer, Inc. | Prosthetic implant and method of making same |
US5605887A (en) * | 1993-03-01 | 1997-02-25 | Fibratek, Inc. | Therapeutic fibrinogen compositions |
US5709854A (en) * | 1993-04-30 | 1998-01-20 | Massachusetts Institute Of Technology | Tissue formation by injecting a cell-polymeric solution that gels in vivo |
US5876208A (en) * | 1993-12-06 | 1999-03-02 | Minnesota Mining And Manufacturing Company | Optionally crosslinkable coatings for orthodontic devices |
US5866630A (en) * | 1993-12-06 | 1999-02-02 | Minnesota Mining And Manufacturing Company | Optionally crosslinkable coatings compositions and methods of use |
US6025334A (en) * | 1994-04-28 | 2000-02-15 | Les Laboratoires Aeterna Inc. | Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US5496375A (en) * | 1994-09-14 | 1996-03-05 | Zimmer, Inc. | Prosthetic implant with circumferential porous pad having interlocking tabs |
US5713374A (en) * | 1995-02-10 | 1998-02-03 | The Hospital For Joint Diseases Orthopaedic Institute | Fixation method for the attachment of wound repair materials to cartilage defects |
US5723010A (en) * | 1995-03-31 | 1998-03-03 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
US5876451A (en) * | 1995-03-31 | 1999-03-02 | Toyo Boseki Kabushiki Kaisha | Medical device and method for producing the same |
US5714371A (en) * | 1995-05-12 | 1998-02-03 | Schering Corporation | Method for refolding insoluble aggregates of hepatitis C virus protease |
US6504079B2 (en) * | 1995-06-07 | 2003-01-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
US5734959A (en) * | 1995-10-12 | 1998-03-31 | Zimmer, Inc. | Method of making an orthopaedic implant having a porous surface using an organic binder |
US20020004038A1 (en) * | 1996-04-30 | 2002-01-10 | Baugh Robert F. | Autologous platelet gel spray delivery system |
US5866415A (en) * | 1997-03-25 | 1999-02-02 | Villeneuve; Peter E. | Materials for healing cartilage and bone defects |
US6183737B1 (en) * | 1997-10-30 | 2001-02-06 | The General Hospital Corporation | Bonding of cartilage pieces using isolated chondrocytes and a biological gel |
US6187329B1 (en) * | 1997-12-23 | 2001-02-13 | Board Of Regents Of The University Of Texas System | Variable permeability bone implants, methods for their preparation and use |
US20020012705A1 (en) * | 1998-04-08 | 2002-01-31 | Chondros, Inc. | Polymer constructs |
US6514522B2 (en) * | 1998-04-08 | 2003-02-04 | Chondros, Inc. | Polymer constructs |
US6171610B1 (en) * | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
US6022361A (en) * | 1998-10-09 | 2000-02-08 | Biointerventional Corporation | Device for introducing and polymerizing polymeric biomaterials in the human body and method |
US6685987B2 (en) * | 1999-03-12 | 2004-02-03 | Zimmer Technology, Inc. | Enhanced fatigue strength orthopaedic implant with porous coating and method of making same |
US6338878B1 (en) * | 1999-04-28 | 2002-01-15 | Alcatel | Method to improve degree of cure for ultraviolet curable optical fiber coating by actively removing heat from the coating during irradiation |
US20020009805A1 (en) * | 1999-07-06 | 2002-01-24 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Scaffold matrix and tissue maintaining systems |
US6513455B2 (en) * | 1999-08-23 | 2003-02-04 | Lafeber, Iii Theodore J. | Pet cage scenery and toys made of molded paper pulp |
US6336930B1 (en) * | 2000-03-07 | 2002-01-08 | Zimmer, Inc. | Polymer filled bone plate |
US6676971B2 (en) * | 2000-03-13 | 2004-01-13 | Biocure, Inc. | Embolic compositions |
US20040030404A1 (en) * | 2000-05-31 | 2004-02-12 | Michaela Noll | Method for cultivating a cartilage replacement and a biomatrix produced according to this method |
US6991652B2 (en) * | 2000-06-13 | 2006-01-31 | Burg Karen J L | Tissue engineering composite |
US20030009235A1 (en) * | 2000-07-19 | 2003-01-09 | Albert Manrique | Osteoimplant and method of making same |
US20040033212A1 (en) * | 2000-07-29 | 2004-02-19 | Thomson Brian Mark | Tissue implant |
US20020183850A1 (en) * | 2000-08-28 | 2002-12-05 | Felt Jeffrey C. | Method and system for mammalian joint resurfacing |
US20060024373A1 (en) * | 2000-11-14 | 2006-02-02 | N.V.R. Labs Ltd. | Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants |
US20040030406A1 (en) * | 2000-12-06 | 2004-02-12 | Mitsuo Ochi | Tissue equivalent for transplantation and process for producing the same |
US6852330B2 (en) * | 2000-12-21 | 2005-02-08 | Depuy Mitek, Inc. | Reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
US6697143B2 (en) * | 2001-02-12 | 2004-02-24 | Viztec, Inc. | Electrooptical displays constructed with polymerization initiating and enhancing elements positioned between substrates |
US20060024826A1 (en) * | 2001-02-23 | 2006-02-02 | University Of Massachusetts, A Massachusetts Corporation | Tympanic membrane patch |
US20030040113A1 (en) * | 2001-03-23 | 2003-02-27 | Histogenics Corporation | Composition and methods for the production of biological tissues and tissue constructs |
US20060029679A1 (en) * | 2001-04-09 | 2006-02-09 | Medtronic, Inc. | Autologous platelet gel having beneficial geometric shapes and methods of making the same |
US20030039695A1 (en) * | 2001-08-10 | 2003-02-27 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Collagen carrier of therapeutic genetic material, and method |
US20050026133A1 (en) * | 2002-01-31 | 2005-02-03 | Asahi Techno Glass Corporation | Cryopreservation medium for primate embryo stem cells and cryopreservation method |
US20080009942A1 (en) * | 2002-03-22 | 2008-01-10 | Histogenics Corp. | Method for in situ repair of injured, damaged, diseased or aged articular cartilage |
US20080051624A1 (en) * | 2002-06-07 | 2008-02-28 | Bonutti Peter M | Scaffold and method for implanting cells |
US20040127987A1 (en) * | 2002-06-13 | 2004-07-01 | Evans Douglas G. | Devices and methods for treating defects in the tissue of a living being |
US20040007890A1 (en) * | 2002-06-26 | 2004-01-15 | Rbw Industries, Inc. | Room expansion system |
US6840960B2 (en) * | 2002-09-27 | 2005-01-11 | Stephen K. Bubb | Porous implant system and treatment method |
US20110009963A1 (en) * | 2002-10-18 | 2011-01-13 | Depuy Mitek, Inc. | Biocompatible scaffold for ligament or tendon repair |
US7488348B2 (en) * | 2003-05-16 | 2009-02-10 | Musculoskeletal Transplant Foundation | Cartilage allograft plug |
US20050032015A1 (en) * | 2003-08-07 | 2005-02-10 | Mcsurdy David W. | System and method for palatal expansion |
US20050038520A1 (en) * | 2003-08-11 | 2005-02-17 | Francois Binette | Method and apparatus for resurfacing an articular surface |
US20050043805A1 (en) * | 2003-08-11 | 2005-02-24 | Chudik Steven C. | Devices and methods used for shoulder replacement |
US20070014867A1 (en) * | 2003-08-20 | 2007-01-18 | Histogenics Corp | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof |
US20050043814A1 (en) * | 2003-08-20 | 2005-02-24 | Akihiko Kusanagi | Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof |
US7875296B2 (en) * | 2003-11-26 | 2011-01-25 | Depuy Mitek, Inc. | Conformable tissue repair implant capable of injection delivery |
US7316822B2 (en) * | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US20050152882A1 (en) * | 2003-12-11 | 2005-07-14 | Isto Technologies | Particulate cartilage system |
US8652507B2 (en) * | 2003-12-11 | 2014-02-18 | Zimmer, Inc. | Juvenile cartilage composition |
US20120009270A1 (en) * | 2003-12-11 | 2012-01-12 | Isto Technologies, Inc. | Treatment methods using a particulate cartilage system |
US20120009224A1 (en) * | 2003-12-11 | 2012-01-12 | Isto Technologies, Inc. | Particulate cartilage treatment composition |
US7879604B2 (en) * | 2004-02-20 | 2011-02-01 | Isto Technoliges, Inc. | Intervertebral disk repair, methods and devices therefor |
US20080039940A1 (en) * | 2004-03-11 | 2008-02-14 | Kouji Hashimoto | Biological Tissue Sheet, Method Of Forming The Same And Transplantation Method By Using The Sheet |
US20060041270A1 (en) * | 2004-05-07 | 2006-02-23 | Jay Lenker | Medical access sheath |
US20070031471A1 (en) * | 2004-06-23 | 2007-02-08 | Minu, L.L.C. | Uses of Amniotic Membranes as Biocompatible Devices |
US20060009779A1 (en) * | 2004-06-29 | 2006-01-12 | Keith Collins | Devices for injecting a curable biomaterial into a intervertebral space |
US20060008530A1 (en) * | 2004-07-12 | 2006-01-12 | Isto Technologies, Inc. | Tissue matrix system |
US20060019389A1 (en) * | 2004-07-22 | 2006-01-26 | Avner Yayon | Porous plasma protein matrices and methods for preparation thereof |
US20070041952A1 (en) * | 2005-04-18 | 2007-02-22 | Duke University | Three-dimensional fiber scaffolds for tissue engineering |
US20070038299A1 (en) * | 2005-08-12 | 2007-02-15 | Arthrotek, Inc | Multilayer microperforated implant |
US20080033333A1 (en) * | 2006-08-04 | 2008-02-07 | Macphee Martin | Solid dressing for treating wounded tissue |
US20080033331A1 (en) * | 2006-08-04 | 2008-02-07 | Macphee Martin | Solid dressing for treating wounded tissue |
US20080033332A1 (en) * | 2006-08-04 | 2008-02-07 | Macphee Martin | Solid dressing for treating wounded tissue |
US20080031934A1 (en) * | 2006-08-04 | 2008-02-07 | Macphee Martin | Processes for the production of solid dressings for treating wounded tissue |
US20080039954A1 (en) * | 2006-08-08 | 2008-02-14 | Howmedica Osteonics Corp. | Expandable cartilage implant |
US20100015202A1 (en) * | 2007-03-06 | 2010-01-21 | Semler Eric J | Cancellous construct with support ring for repair of osteochondral defects |
Cited By (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765165B2 (en) | 2003-12-11 | 2014-07-01 | Zimmer, Inc. | Particulate cartilage system |
US8518433B2 (en) | 2003-12-11 | 2013-08-27 | Zimmer, Inc. | Method of treating an osteochondral defect |
US8784863B2 (en) | 2003-12-11 | 2014-07-22 | Zimmer, Inc. | Particulate cadaveric allogenic cartilage system |
US8834914B2 (en) | 2003-12-11 | 2014-09-16 | Zimmer, Inc. | Treatment methods using a particulate cadaveric allogenic juvenile cartilage particles |
US8652507B2 (en) | 2003-12-11 | 2014-02-18 | Zimmer, Inc. | Juvenile cartilage composition |
US8524268B2 (en) | 2003-12-11 | 2013-09-03 | Zimmer, Inc. | Cadaveric allogenic human juvenile cartilage implant |
US8480757B2 (en) | 2005-08-26 | 2013-07-09 | Zimmer, Inc. | Implants and methods for repair, replacement and treatment of disease |
US8497121B2 (en) | 2006-12-20 | 2013-07-30 | Zimmer Orthobiologics, Inc. | Method of obtaining viable small tissue particles and use for tissue repair |
US8906110B2 (en) | 2007-01-24 | 2014-12-09 | Musculoskeletal Transplant Foundation | Two piece cancellous construct for cartilage repair |
US9138318B2 (en) | 2007-04-12 | 2015-09-22 | Zimmer, Inc. | Apparatus for forming an implant |
US20120116523A1 (en) * | 2009-07-10 | 2012-05-10 | Milux Holding Sa | Joint device and method |
US20190110896A1 (en) * | 2009-07-10 | 2019-04-18 | Peter Forsell | Joint device and method |
US9375315B2 (en) * | 2009-07-10 | 2016-06-28 | Peter Forsell | Joint device and method |
US11305035B2 (en) | 2010-05-14 | 2022-04-19 | Musculoskeletal Transplant Foundatiaon | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US8883210B1 (en) | 2010-05-14 | 2014-11-11 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US9352003B1 (en) | 2010-05-14 | 2016-05-31 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10130736B1 (en) | 2010-05-14 | 2018-11-20 | Musculoskeletal Transplant Foundation | Tissue-derived tissuegenic implants, and methods of fabricating and using same |
US10232085B2 (en) | 2011-02-14 | 2019-03-19 | Mimedx Group, Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
US10105397B2 (en) | 2011-02-14 | 2018-10-23 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US10376546B2 (en) | 2011-02-14 | 2019-08-13 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US11931384B2 (en) | 2011-02-14 | 2024-03-19 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US10869951B2 (en) | 2011-02-14 | 2020-12-22 | Mimedx Group, Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
US10105398B2 (en) | 2011-02-14 | 2018-10-23 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US10869952B2 (en) | 2011-02-14 | 2020-12-22 | Mimedx Group, Inc. | Tissue grafts modified with a cross-linking agent and method of making and using the same |
US11103536B2 (en) | 2011-02-14 | 2021-08-31 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US11235007B2 (en) | 2011-02-14 | 2022-02-01 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US11219647B2 (en) | 2011-02-14 | 2022-01-11 | Mimedx Group, Inc. | Micronized placental tissue compositions and methods of making and using the same |
US9681953B2 (en) * | 2011-03-31 | 2017-06-20 | Inje University Industry-Academic Cooperation Foundation | Complex support body for regenerating bone-cartilage, method for manufacturing thereof, and composition for treating bone and cartilage related diseases comprising same as active ingredient |
US20140012393A1 (en) * | 2011-03-31 | 2014-01-09 | Inje University Industry-Academic Cooperation Foundation | Complex support body for regenerating bone-cartilage, method for manufacturing thereof, and composition for treating bone and cartilage related diseases comprising same as active ingredient |
US8834928B1 (en) | 2011-05-16 | 2014-09-16 | Musculoskeletal Transplant Foundation | Tissue-derived tissugenic implants, and methods of fabricating and using same |
US11066646B2 (en) | 2011-06-29 | 2021-07-20 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US11851682B2 (en) | 2011-06-29 | 2023-12-26 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US10597638B2 (en) | 2011-06-29 | 2020-03-24 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US9133438B2 (en) | 2011-06-29 | 2015-09-15 | Biorestorative Therapies, Inc. | Brown fat cell compositions and methods |
US9463206B2 (en) | 2011-12-22 | 2016-10-11 | Mimedx Group, Inc. | Cross-linked dehydrated placental tissue grafts and methods for making and using the same |
US8904664B2 (en) | 2012-08-15 | 2014-12-09 | Mimedx Group, Inc. | Dehydration device and methods for drying biological materials |
US10857266B2 (en) | 2012-08-15 | 2020-12-08 | Mimedx Group, Inc. | Reinforced placental tissue grafts and methods of making and using the same |
US11607430B2 (en) | 2012-08-15 | 2023-03-21 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
WO2014028327A1 (en) * | 2012-08-15 | 2014-02-20 | Mimedx Group Inc. | Micronized placental tissue compositions and methods of making and using the same |
US11338063B2 (en) | 2012-08-15 | 2022-05-24 | Mimedx Group, Inc. | Placental tissue grafts modified with a cross-linking agent and methods of making and using the same |
US9943551B2 (en) | 2012-08-15 | 2018-04-17 | Mimedx Group, Inc. | Tissue grafts composed of micronized placental tissue and methods of making and using the same |
US9180145B2 (en) | 2012-10-12 | 2015-11-10 | Mimedx Group, Inc. | Compositions and methods for recruiting and localizing stem cells |
US10159744B2 (en) | 2012-11-19 | 2018-12-25 | Mimedx Group, Inc. | Cross-linked collagen comprising metallic anticancer agents |
US10441664B2 (en) | 2012-11-19 | 2019-10-15 | Mimedx Group, Inc. | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent |
US10167447B2 (en) | 2012-12-21 | 2019-01-01 | Zimmer, Inc. | Supports and methods for promoting integration of cartilage tissue explants |
US9827293B2 (en) | 2013-01-17 | 2017-11-28 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US11690896B2 (en) | 2013-01-17 | 2023-07-04 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US10517931B2 (en) | 2013-01-17 | 2019-12-31 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9655948B1 (en) | 2013-01-17 | 2017-05-23 | Mimedx Group, Inc. | Non-surgical, localized delivery of compositions for placental growth factors |
US9662355B2 (en) | 2013-01-18 | 2017-05-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US10111910B2 (en) | 2013-01-18 | 2018-10-30 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US11000553B2 (en) | 2013-01-18 | 2021-05-11 | Mimedx Group, Inc. | Placental tissue composition for for treating cardiac tissue damage |
US11497791B1 (en) | 2013-01-18 | 2022-11-15 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
US10206977B1 (en) | 2013-01-18 | 2019-02-19 | Mimedx Group, Inc. | Isolated placental stem cell recruiting factors |
US11648281B2 (en) | 2013-01-18 | 2023-05-16 | Mimedx Group, Inc. | Methods for treating cardiac conditions |
US10029030B2 (en) | 2013-03-15 | 2018-07-24 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
US11389565B2 (en) | 2013-03-15 | 2022-07-19 | Mimedx Group, Inc. | Molded placental tissue compositions and methods of making and using the same |
US10941383B2 (en) | 2013-04-19 | 2021-03-09 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US10167449B2 (en) | 2013-04-19 | 2019-01-01 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US11667892B2 (en) | 2013-04-19 | 2023-06-06 | Biorestorative Therapies, Inc. | Human brown adipose derived stem cells and uses |
US9446142B2 (en) | 2013-05-28 | 2016-09-20 | Mimedx Group, Inc. | Polymer chelator conjugates |
US11779610B2 (en) | 2013-07-30 | 2023-10-10 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for using same |
US10596201B2 (en) | 2013-07-30 | 2020-03-24 | Musculoskeletal Transplant Foundation | Delipidated, decellularized adipose tissue matrix |
US10092600B2 (en) | 2013-07-30 | 2018-10-09 | Musculoskeletal Transplant Foundation | Method of preparing an adipose tissue derived matrix |
US11191788B2 (en) | 2013-07-30 | 2021-12-07 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US10842824B2 (en) | 2014-01-17 | 2020-11-24 | Mimedx Group, Inc. | Method for inducing angiogenesis |
US10052351B2 (en) | 2014-01-17 | 2018-08-21 | Mimedx Group, Inc. | Method for inducing angiogenesis |
US10617785B2 (en) | 2014-08-28 | 2020-04-14 | Mimedx Group, Inc. | Collagen reinforced tissue grafts |
US11596517B2 (en) | 2015-05-21 | 2023-03-07 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US10531957B2 (en) | 2015-05-21 | 2020-01-14 | Musculoskeletal Transplant Foundation | Modified demineralized cortical bone fibers |
US11524093B2 (en) | 2015-07-24 | 2022-12-13 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US10912864B2 (en) | 2015-07-24 | 2021-02-09 | Musculoskeletal Transplant Foundation | Acellular soft tissue-derived matrices and methods for preparing same |
US11052175B2 (en) | 2015-08-19 | 2021-07-06 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US11806443B2 (en) | 2015-08-19 | 2023-11-07 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
US11938245B2 (en) | 2015-08-19 | 2024-03-26 | Musculoskeletal Transplant Foundation | Cartilage-derived implants and methods of making and using same |
CN113198047A (en) * | 2021-05-14 | 2021-08-03 | 西安市红会医院 | Preparation method of cartilage regeneration support material for orthopedic sports trauma |
Also Published As
Publication number | Publication date |
---|---|
US20120107384A1 (en) | 2012-05-03 |
AU2008240191B2 (en) | 2013-09-19 |
CA2684040C (en) | 2016-12-06 |
EP2134297B1 (en) | 2017-03-08 |
EP2134297A4 (en) | 2013-05-01 |
CA2684040A1 (en) | 2008-10-23 |
AU2008240191A1 (en) | 2008-10-23 |
EP2134297A1 (en) | 2009-12-23 |
WO2008128075A1 (en) | 2008-10-23 |
US9138318B2 (en) | 2015-09-22 |
AU2008240191A2 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9138318B2 (en) | Apparatus for forming an implant | |
CN109276348B (en) | Bone implant for encapsulating bone material | |
CA2353240C (en) | Bone material and collagen combination for repair of injured joints | |
US8137354B2 (en) | Localized cartilage defect therapy | |
EP1647288B1 (en) | Method and apparatus for repairing bone | |
JP2019520900A (en) | Indirect method of joint tissue repair | |
KR20060031808A (en) | Osteoimplants and methods for their manufacture | |
JP2008521502A (en) | In vivo treatment and repair method for meniscal injury | |
CN115624569A (en) | Process for preparing wound repair agent composition, tube and device | |
ZA200509983B (en) | A method for cell implantation | |
CN113015546B (en) | Bone material hydration apparatus and method | |
KR20190101298A (en) | Demineralized bone matrix having improved handling characteristics | |
JP2022500100A (en) | Bone material mixing and dispensing equipment and methods | |
CN107683130A (en) | Implant and application method including oxygen sterol | |
KR101429857B1 (en) | Method for manufacturing composite bilayer fiber mat for bone hemorrhage application | |
US10500307B2 (en) | Materials and methods for repair of cartilage defects | |
CN101352581B (en) | Adhesion agent for fixing articular cartilage repair implant and use of human fibrinogen in preparing the adhesion agent | |
CN111526828A (en) | Bone material delivery system | |
JP2009542313A (en) | Drug delivery device, kit and method for intraoperative local drug treatment of bone surface | |
EP3456363B1 (en) | Composition for regenerating bony tissue, method for preparation and use thereof | |
EP3664746A1 (en) | Multiphasic tissue scaffold constructs | |
RU2462255C1 (en) | Organ-specific regenerant gi | |
WO2002040963A2 (en) | Biologically active composites and methods for their production and use | |
TW420604B (en) | An absorbable calcium phosphate biomedical compound material particle and it's manufacturing procedure | |
WO2023201195A2 (en) | Systems, methods, and devices of exosome delivery for bone healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ISTO TECHNOLOGIES, INC., MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAO, JIAN Q.;WALTHALL, BEN;GAO, JIZONG;AND OTHERS;REEL/FRAME:021554/0546 Effective date: 20080916 Owner name: ZIMMER, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:YAO, JIAN Q.;WALTHALL, BEN;GAO, JIZONG;AND OTHERS;REEL/FRAME:021554/0546 Effective date: 20080916 |
|
AS | Assignment |
Owner name: VELOCITY FINANCIAL GROUP INC., ITS SUCCESSORS AND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ISTO TECHNOLOGIES, INC., A DELAWARE CORP.;REEL/FRAME:021816/0851 Effective date: 20080930 |
|
AS | Assignment |
Owner name: ISTO TECHNOLOGIES, INC., MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VELOCITY VENTURE FUNDING, LLC;REEL/FRAME:029046/0505 Effective date: 20120928 |
|
AS | Assignment |
Owner name: ZIMMER, INC., INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ISTO TECHNOLOGIES, INC.;REEL/FRAME:029406/0240 Effective date: 20121101 |
|
AS | Assignment |
Owner name: MIDCAP FINANCIAL SBIC, LP, MARYLAND Free format text: SECURITY INTEREST;ASSIGNOR:ISTO TECHNOLOGIES, INC.;REEL/FRAME:034805/0001 Effective date: 20141222 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ISTO TECHNOLOGIES, INC., MISSOURI Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MIDCAP FUNDING XVIII TRUST, AS SUCCESSOR IN INTEREST TO MIDCAP FINANCIAL SBIC, LP;REEL/FRAME:038903/0645 Effective date: 20160603 |